US8440237B2 - Botanical anti-acne formulations - Google Patents

Botanical anti-acne formulations Download PDF

Info

Publication number
US8440237B2
US8440237B2 US12/768,450 US76845010A US8440237B2 US 8440237 B2 US8440237 B2 US 8440237B2 US 76845010 A US76845010 A US 76845010A US 8440237 B2 US8440237 B2 US 8440237B2
Authority
US
United States
Prior art keywords
extract
skin
oil
composition
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US12/768,450
Other versions
US20100303854A1 (en
Inventor
Michelle Hines
Tiffany Florence
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kay Mary Inc
Original Assignee
Kay Mary Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12/768,450 priority Critical patent/US8440237B2/en
Application filed by Kay Mary Inc filed Critical Kay Mary Inc
Assigned to MARY KAY INC. reassignment MARY KAY INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FLORENCE, TIFFANY, HINES, MICHELLE
Publication of US20100303854A1 publication Critical patent/US20100303854A1/en
Priority to US13/326,138 priority patent/US8481090B2/en
Application granted granted Critical
Publication of US8440237B2 publication Critical patent/US8440237B2/en
Priority to US13/907,500 priority patent/US8747926B2/en
Priority to US14/266,382 priority patent/US9561198B2/en
Priority to US15/388,541 priority patent/US10682381B2/en
Priority to US16/260,875 priority patent/US10953058B2/en
Priority to US17/173,746 priority patent/US11638735B2/en
Priority to US18/123,711 priority patent/US20240050505A1/en
Priority to US18/538,812 priority patent/US20240108673A1/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/327Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02Algae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02Algae
    • A61K36/03Phaeophycota or phaeophyta (brown algae), e.g. Fucus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/61Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706Algae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706Algae
    • A61K8/9711Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9728Fungi, e.g. yeasts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9755Gymnosperms [Coniferophyta]
    • A61K8/9767Pinaceae [Pine family], e.g. pine or cedar
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin

Definitions

  • the present invention relates generally to compositions that include botanical extracts that can be used to reduce the redness associated with acne lesions, improve skin clarity through dermal remodeling, and protect the skin from additional acne breakouts.
  • the compositions of the present invention can also be used to treat or prevent a wide variety of skin conditions.
  • the present invention concerns topical skin care compositions that include Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, or Mushroom extract, or any combination thereof.
  • the composition includes a combination of Epilobium angustifolium (Canadian Willowherb) extract, Arctium lappa (Burdock) root extract, and Cystoseira amentacea/Caespitosa Brachycarpa extract.
  • Salicylic acid, benzoic acid, benzoyl peroxide, and tretinoin are known anti-acne ingredients. Problems/side effects associated with these ingredients include dry skin, scaly skin, and flaky skin. They can also irritate the skin, which causes the skin to appear red and feel like it is burning. Such irritation adds to the already painful sensation associated with the presence of acne on the skin.
  • the present invention overcomes deficiencies in the art by providing anti-acne compositions that can treat, reduce, or prevent the appearance of the signs of acne on skin (e.g., comedones, papules, pustules, nodulocystic lesions, skin redness, etc.).
  • signs of acne on skin e.g., comedones, papules, pustules, nodulocystic lesions, skin redness, etc.
  • compositions can include Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, or Mushroom extract, or any combination thereof.
  • the composition includes a combination of Epilobium angustifolium (Canadian Willowherb) extract, Arctium lappa (Burdock) root extract, and Cystoseira amentacea/Caespitosa Brachycarpa extract.
  • the combination of ingredients can be Ribes nigrum (Black curant) leaf extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, hydrolyzed soy protein, Epilobium angustifolium (Canadian Willowherb) extract, and Arctium lappa (Burdock) root extract.
  • the combination of ingredients can be Ribes nigrum (Black curant) leaf extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, hydrolyzed soy protein, Epilobium angustifolium (Canadian Willowherb) extract, Arctium lappa (Burdock) root extract, navy bean extract, and mushroom extract.
  • compositions can also include an added benefit of reducing or preventing the appearance of dry, scaly, flaky skin and skin irritation. That is, the compositions of the present invention can reduce, prevent, or treat the signs of acne on skin while also reducing or preventing or avoiding side-effects such as dry, scaly, flaky skin and skin irritation. These side-effects can be reduced or prevented or avoided even if anti-acne ingredients that are known to cause such side-effects (e.g., salicylic acid, benzoic acid, benzoyl peroxide, tretinoin, etc.) are incorporated into the compositions of the present invention at effective amounts.
  • anti-acne ingredients e.g., salicylic acid, benzoic acid, benzoyl peroxide, tretinoin, etc.
  • compositions of the present invention can include Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Soy extract, Navy bean extract, or Mushroom extract, or any one of, any combination of, or all of such ingredients.
  • compositions can also include other anti-acne ingredients, even those known to cause undesirable side-effects such as dry, flaky, scaly skin or skin irritation (e.g., salicylic acid, benzoic acid, benzoyl peroxide, tretinoin etc.).
  • the compositions are formulated into topical skin care compositions.
  • the compositions can be cosmetic compositions.
  • the compositions can be included in a cosmetic vehicle.
  • Non-limiting examples of cosmetic vehicles are disclosed in other sections of this specification and are known to those of skill in the art.
  • Examples of cosmetic vehicles include emulsions (e.g., oil-in-water and water-in-oil emulsions), creams, lotions, solutions (e.g., aqueous or hydro-alcoholic solutions), anhydrous bases (e.g., lipstick or a powder), gels, and ointments.
  • the compositions of the present invention can be included in anti-aging, cleansing, or moisturizing products.
  • compositions can also be formulated for topical skin application at least 1, 2, 3, 4, 5, 6, 7, or more times a day during use.
  • compositions can be storage stable or color stable, or both.
  • the viscosity of the composition can be selected to achieve a desired result (e.g., depending on the type of composition desired, the viscosity of such composition can be from about 1 cps to well over 1 million cps or any range or integer derivable therein (e.g., 2 cps, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200000, 300000, 400000, 500000, 600000, 700000, 800000,
  • compositions in non-limiting aspects can have a pH of about 6 to about 9.
  • the pH can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14.
  • the compositions can be sunscreens having a sun protection factor (SPF) of 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or more.
  • SPF sun protection factor
  • compositions can be oil-free, substantially anhydrous, and/or anhydrous.
  • Other aspects include compositions having water.
  • compositions of the present invention can include from about 0.001% to about 50%, by weight, of Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, or Mushroom extract, or any combination thereof.
  • the amount of such ingredients within a composition can be modified below, within, or above this range based on the desired results. Therefore, the amount of such ingredients can include less than 0.0001%.
  • the compositions can include 0.0001, 0.0002 . . . 0.002, 0.003, 0.004 . . .
  • Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, or Mushroom extract, or any combination thereof.
  • the composition can include a dermatologically acceptable vehicle or carrier.
  • vehicle or carrier can include any one of, any combination of, or all of the following ingredients: water; salicylic acid or benzoyl peroxide or a combination thereof; phenoxyethanol; butylene glycol; citric acid; propylene glycol; methylparaben or propylparaben or a combination thereof glycerin; chlorphenesin; and/or sodium metabisulfite.
  • compositions of the present invention can also be modified to have a desired oxygen radical absorbance capacity (ORAC) value.
  • ORAC oxygen radical absorbance capacity
  • the compositions of the present invention can be modified to have an ORAC value per mg of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 95, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 15000, 20000, 30000, 50000, 100000 or more or any range derivable therein.
  • the compositions can further include a vitamin, a mineral, an essential fatty acid, an amino acid, a flavonoid, and/or a protein, or a combination thereof.
  • vitamins include the B vitamins (e.g., B1, B2, B6, B12, niacin, folic acid, biotin, and pantothenic acid), vitamin C, vitamin D, vitamin E (e.g., tocopherol or tocopheryl acetate), vitamin A (e.g., palmitate, retinyl palmitate, or retinoic acid), and vitamin K.
  • vitamins include the B vitamins (e.g., B1, B2, B6, B12, niacin, folic acid, biotin, and pantothenic acid), vitamin C, vitamin D, vitamin E (e.g., tocopherol or tocopheryl acetate), vitamin A (e.g., palmitate, retinyl palmitate, or retinoic acid), and vitamin K.
  • minerals include iron, potassium,
  • Non-limiting examples of essential fatty acids include Omega 3 (linolenic acid), Omega 6 (linoleic acid) and Omega 9 (oleic acid) essential fatty acid, or a combination thereof.
  • Non-limiting examples of amino acids include essential amino acids (e.g., lysine, leucine, isoleucine, methionine, phenylalanine, threonine, tryptophan, valine, histidine, or arginine) and non-essential amino acids (e.g., serine, asparagine, glutamine, aspartic acid, glutamic acid, alanine, tyrosine, cysteine, glycine, or proline).
  • Non-limiting examples of flavonoids include anthocyanin compounds (e.g., cyanidin-3-glucoside and cyanidin-3-rutinoside).
  • compositions can include a triglyceride, a preservative, an essential oil, a UV absorption ingredient, and/or additional ingredients described in the specification and known in the art, and any combination thereof.
  • triglycerides include small, medium, and large chain triglycerides.
  • preservatives include methylparaben, propylparaben, or a mixture of methylparaben and propylparaben.
  • Non-limiting examples of essential oils are those described in the specification and those known to a person of ordinary skill in the art.
  • UV absorption ingredients include dibenzoylmethane derivatives (e.g., avobenzone), octocrylene, oxybenzone, homosalate, octisalate, octyl methoxycinnamate, ecamsule, titanium dioxide, zinc oxide, etc., and others described in the specification and known to those in the art, and any combination thereof.
  • Also disclosed is a method of treating or preventing a skin condition comprising topical application of a composition comprising Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, or Mushroom extract, or any combination thereof, wherein the topical application of the composition treats the skin condition.
  • a composition comprising Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo)
  • the method can include topical application of the composition to a portion of skin in need of such composition (e.g., skin having a skin condition), wherein topical application reduces or prevents the skin condition when compared to skin that has a skin condition and that has not been treated with the composition.
  • a portion of skin in need of such composition e.g., skin having a skin condition
  • topical application reduces or prevents the skin condition when compared to skin that has a skin condition and that has not been treated with the composition.
  • Non-limiting examples of skin conditions include acne, symptoms associated with acne (e.g., presence of open or closed comedones, papules, pustules, nodulocystic lesions, skin redness, etc.), pruritus, spider veins, lentigo, age spots, senile purpura, keratosis, melasma, blotches, fine lines or wrinkles, nodules, sun damaged skin, dermatitis (including, but not limited to seborrheic dermatitis, nummular dermatitis, contact dermatitis, atopic dermatitis, exfoliative dermatitis, perioral dermatitis, and stasis dermatitis), psoriasis, folliculitis, rosacea, impetigo, erysipelas, erythrasma, eczema, and other inflammatory skin conditions.
  • acne e.g., presence of open or closed comedone
  • the skin condition can be caused by exposure to UV light, age, irradiation, chronic sun exposure, environmental pollutants, air pollution, wind, cold, heat, chemicals, disease pathologies, smoking, or lack of nutrition.
  • the skin can be facial skin or non-facial skin (e.g., arms, legs, hands, chest, back, feet, etc.).
  • the method can further comprise identifying a person in need of skin treatment.
  • the person can be a male or female.
  • the age of the person can be at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or more years old, or any range derivable therein.
  • the method can also include topically applying an amount effective to: increase the stratum corneum turnover rate of the skin; increase collagen synthesis in fibroblasts; increase cellular anti-oxidant defense mechanisms (e.g., exogenous additions of anti-oxidants can bolster, replenish, or prevent the loss of cellular antioxidants such as catalase and glutathione in skin cells (e.g., keratinocytes, melanocytes, langerhans cells, etc.) which will reduce or prevent oxidative damage to the skin, cellular, proteins, and lipids); inhibit melanin production in melanocytes; reduce or prevent oxidative damage to skin (including reducing the amount lipid peroxides and/or protein oxidation in the skin).
  • cellular anti-oxidant defense mechanisms e.g., exogenous additions of anti-oxidants can bolster, replenish, or prevent the loss of cellular antioxidants such as catalase and glutathione in skin cells (e.g., keratinocytes, melanocytes,
  • compositions of the present invention can decrease the amount of internal oxidation and/or external oxidative damage in a cell.
  • the compositions can increase collagen synthesis in a cell.
  • the compositions can also reduce skin inflammation, such as by reducing inflammatory cytokine production in a cell.
  • Non-limiting examples of such cells include human epidermal keratinocyte, human fibroblast dermal cell, human melanocytes, three dimensional human cell-derived in vitro tissue equivalents comprising human keratinocytes, human fibroblasts, or human melanocytes, or any combination thereof (e.g., combination of human keratinocytes and human fibroblasts or a combination of human keratinocytes and human melanocytes).
  • the method can include incorporating botanical extracts selected from the group consisting of Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, or Mushroom extract, or any combination thereof, into a topical anti-acne formulation which includes an anti-acne agent known to cause side-effects, wherein the addition of the botanical extract into the composition reduces or prevents the side-effects to the skin.
  • the anti-acne agent can be salicylic acid, benzo
  • compositions of the present invention can also be used to reduce side-effects associated with topical application of a pharmaceutical ingredient to skin.
  • the method can include incorporating botanical extracts selected from the group consisting of Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, or Mushroom extract, or any combination thereof, or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or all 10 of the aforementioned ingredients, into a topical skin formulation which includes a pharmaceutical ingredient known to cause side-effects, wherein the addition of the botanical extract into the composition reduces or prevents the side-effects to the group consisting
  • the composition includes Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, and Cystoseira amentacea/Caespitosa Brachycarpa extract.
  • the pharmaceutical ingredient can be an ingredient selected from the group consisting of agents used to treat rosacea, analgesics, anesthetics, anorectals, antihistamines, anti-inflammatory agents including non-steroidal anti-inflammatory drugs, antibiotics, antifungals, antivirals, antimicrobials, anti-cancer actives, scabicides, pediculicides, antineoplastics, antiperspirants, antipruritics, antipsoriatic agents, antiseborrheic agents, biologically active proteins and peptides, burn treatment agents, cauterizing agents, depigmenting agents, depilatories, diaper rash treatment agents, enzymes, hair growth stimulants, hair growth retardants including DFMO and its salts and analogs, hemostatics, kerotolytics, canker sore treatment agents, cold sore treatment agents, dental and periodontal treatment agents, photosensitizing actives, skin protectant/barrier agents, steroids including hormones and corticosteroids, sunburn treatment agents, sunscreen
  • a method of lightening skin or evening skin tone comprising applying the compositions of the present invention to the skin.
  • the method can further comprise identify a person in need of lightening skin or evening skin tone.
  • the methods can further include inhibiting melanogenesis in a skin cell, inhibiting tyrosinase or tyrosinase synthesis in a skin cell, or inhibiting melanin transport to keratinocytes in a skin cell.
  • the composition can act as an alpha melanin stimulatory hormone antagonist.
  • the composition can even out pigmentation of the skin.
  • lightening skin can include reducing the appearance of an age spot, a skin discoloration, or a freckle by topical application of the composition to skin having an age spot, skin discoloration, a freckle, etc.
  • a method of treating hyperpigmentation comprising applying the compositions of the present invention to the skin.
  • the method can also comprise identifying a person in need of treating hyperpigmentation. Additional methods contemplated by the inventor include methods for reducing the appearance of an age spot, a skin discoloration, or a freckle, reducing or preventing the appearance of fine lines or wrinkles in skin, or increasing the firmness of skin.
  • the composition can include Arctium lappa root extract, Epilobium angustifolium extract, or Cystoseira amentacea/Caespitosa Brachycarpa extract or any combination thereof.
  • the erythema can be caused by acne or an acne lesion (e.g., a comedone, a papule, a pustule, or a nodulocystic lesion on the skin).
  • the erythema can be caused by skin sunburn, electrical treatments of skin, skin burns, contact allergies, systemic allergies, skin toxicity, exercise, insect stings, bacterial infection, viral infection, fungal infection, protozoa infection, massage, or windburn.
  • compositions comprising Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, or Mushroom extract, or any combination thereof, can produce synergistic effects.
  • such ingredients can work together synergistically to produce effects that exceed the effects of what would be expected if the extracts were used in separate compositions.
  • Non-limiting synergistic effects include treating or preventing acne and symptoms associated with the same, while also preventing, reducing, or avoiding side-effects such as dry, flaky, scaly skin or skin irritation.
  • Compositions comprising Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, or Mushroom extract, or any combination thereof, can also act in a complementary fashion.
  • such ingredients can be used to treat or prevent acne, treat, prevent, or reduce the appearance of the signs of acne on skin, and reduce, prevent, avoid skin dryness, scaliness, flakiness, or skin irritation, and vice-versa.
  • kits that includes the compositions of the present invention.
  • the composition is comprised in a container.
  • the container can be a bottle, dispenser, or package.
  • the container can dispense a pre-determined amount of the composition.
  • the compositions is dispensed in a spray, dollop, or liquid.
  • the container can include indicia on its surface. The indicia can be a word, an abbreviation, a picture, or a symbol.
  • a product comprising a composition of the present invention.
  • the product can be a cosmetic product.
  • the cosmetic product can be those described in other sections of this specification or those known to a person of skill in the art.
  • Non-limiting examples of products include a moisturizer, a cream, a lotion, a skin softener, a foundation, a night cream, a lipstick, a cleanser, a toner, a sunscreen, a mask, or an anti-aging product.
  • compositions of the present invention can be included into food-based products (e.g., beverages, fortified water, energy drinks, nutritional drinks, solid foods, vitamins, supplements, etc.) and pharmaceutical products (e.g., pills, injectible solutions, drugs, etc.).
  • food-based products e.g., beverages, fortified water, energy drinks, nutritional drinks, solid foods, vitamins, supplements, etc.
  • pharmaceutical products e.g., pills, injectible solutions, drugs, etc.
  • “Supplements” can include vitamins, minerals, herbs or other botanicals, amino acids, enzymes and metabolites. Such supplements are suitable for oral consumption and can be administered orally.
  • compositions and methods for their use can “comprise,” “consist essentially of,” or “consist of” any of the ingredients disclosed throughout the specification.
  • compositions of the present invention can be pharmaceutically or cosmetically elegant.
  • “Pharmaceutically elegant” and/or “cosmetically elegant” describes a composition that has particular tactile properties which feel pleasant on the skin (e.g., compositions that are not too watery or greasy, compositions that have a silky texture, compositions that are non-tacky or sticky, etc.).
  • Pharmaceutically or cosmetically elegant can also relate to the creaminess or lubricity properties of the composition or to the moisture retaining properties of the composition.
  • Topical application means to apply or spread a composition onto the surface of keratinous tissue.
  • Topical skin composition includes compositions suitable for topical application on keratinous tissue. Such compositions are typically dermatologically-acceptable in that they do not have undue toxicity, incompatibility, instability, allergic response, and the like, when applied to skin. Topical skin care compositions of the present invention can have a selected viscosity to avoid significant dripping or pooling after application to skin.
  • Keratinous tissue includes keratin-containing layers disposed as the outermost protective covering of mammals and includes, but is not limited to, skin, hair and nails.
  • non-volatile oil includes those substance that will not evaporate at ordinary or room temperature.
  • mixture when used in the claims and/or specification includes, stirring, blending, dispersing, milling, homogenizing, and other similar methods.
  • the mixing of the components or ingredients of the disclosed compositions can form into a solution. In other embodiments, the mixtures may not form a solution.
  • the ingredients/components can also exist as undissolved colloidal suspensions.
  • substantially and its variations are defined as being largely but not necessarily wholly what is specified as understood by one of ordinary skill in the art, and in one non-limiting embodiment substantially refers to ranges within 10%, within 5%, within 1%, or within 0.5%.
  • the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
  • FIG. 1 Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, and Cystoseira amentacea/Caespitosa Brachycarpa extract, reduce the expression of proinflamattory cytokines IL-8, IL-2, and TNF- ⁇ in human epidermal keratinocytes.
  • Acne is commonly referred to as a disorder of the pilosebaceuous unit, which includes the hair follicle, seabaceous gland, and sebaceous duct.
  • Propionibacterium acnes (“ P. acnes ”), an anaerobic bacteria, is present in all types of human skin and is part of the skin's natural sebum maintenance system.
  • Sebaceous glands produce sebum, which is excreted through the sebaceous duct and travels up the follicle.
  • the sebum mixes with common skin bacteria (including P. acnes ) and dead skin cells that have been shed from the lining of the follicle. While this process is normal, the presence of extra sebum (note that sebum production can increase when stimulated by hormones such as androgens) can increase the possibility that the pilosebaceuous unit becomes plugged/clogged/obstructed. The end result of this is oftentimes an inflammatory response, which can lead to pimples becoming red, swollen, and painful.
  • Noninflammatory acne typically includes the presence of whiteheads and blackheads (respectively referred to as closed and open comedones). These comedones are compact masses of keratin, sebum, and bacteria, which dilate the follicular duct. A comedone forms when a follicle or sebaceous duct is plugged/clogged/obstructed. Inflammatory acne has been characterized by papules (pimples), pustules, and nodulocystic lesions which can lead to scarring of the skin.
  • compositions of the present invention provide for an effective option for treating, reducing, or preventing acne and its associated symptoms (e.g., presence of open and closed comedones, papules, pustules, nodulocystic lesions, skin redness, etc.) by providing topical skin compositions which include natural botanical extracts such as Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, or Mushroom extract, or any combination thereof.
  • natural botanical extracts such as Arctium lappa (Burdock) root extract, Epilobium angustifolium (Can
  • compositions of the present invention also provide a solution to the above-described problems associated with popular anti-acne agents such as salicylic acid, benzoic acid, benzoyl peroxide, and tretinoin.
  • anti-acne agents such as salicylic acid, benzoic acid, benzoyl peroxide, and tretinoin.
  • These types of caustic anti-acne agents can be incorporated into compositions of the present invention at effective amounts while avoiding or substantially reducing the unwanted side-effects.
  • Another advantage is that higher levels of such caustic anti-acne agents can be used, thereby increasing the composition's overall anti-acne effectiveness and the unsightly symptom associated with skin acne.
  • topical skin compositions of the present invention can include Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, or Mushroom extract, or any combination thereof. These ingredients can be obtained from third party sellers.
  • Arctium lappa (Burdock) root extract extract obtained from the root of burdock
  • BURDOCK ROOT EXTRACTTM ORGANIC BURDOCK EXTRACT BG-50TM
  • Indena SA Spain
  • PHYTELENE OF BURDOCK-ROOTS EN 422TM or from Greentech S.A.
  • Epilobium angustifolium (Canadian Willowherb) extract obtained from the flower, leaf, and stem can be purchased from Atrium Innovations (France) under the trade names CANADIAN WILLOWHERB EXTRACTTM (5% clear), CANADIAN WILLOWHERB EXTRACTTM (5% in water), CANADIAN WILLOWHERB EXTRACT-10%TM (in glycerin), from Fytokem (Canada) under the trade names CANADIAN WILLOWHERB EXTRACTTM (5% clear), CANADIAN WILLOWHERB EXTRACTTM (5% in water), CANADIAN WILLOWHERB EXTRACT-10%TM (in glycerin), or from Greentech S.A.
  • Epilobium angustifolium (Canadian Willowherb) extract obtained from the leaf can be purchased from Cosmetochem International (Germany) under the trade name HERBASEC ROSE BAY WILLOW-HERBTM.
  • Pinus sylvestris bark extract extract of the bark of Pinus sylvestris
  • EPICATM trade name
  • Ribes nigrum (Black Currant) leaf extract extract from the leaf of Black Currant
  • Peumus boldus (Boldo) leaf extract extract from the leaves of Boldo
  • BOLDO POWDERED EXTRACTTM from Phytocos (France) under the trade names AROME BOLDOTM, EXTRAIT DE BOLDO LP1TM, and EXTRAIT DE BOLDO SGLPTM, or from Silab (France) under the trade names SCULPTURINETM and SLIMACTIVETM.
  • Spiraea ulmaria (Meadow Sweet) extract obtained from the leaf can be purchased from Gattefosse (Canada) under the trade name CYTOBIO ULMAIRETM.
  • Spiraea ulmaria extract obtained from the whole plant can be purchased from Active Concepts (USA) under the trade name ACB MEADOWSWEET EXTRACTTM, ACB MEADOWSWEET EXTRACT 20%(TM), from Silab (France) under the trade names DERMAPURTM, SEBONORMINETM, and SEBOREGULTM, or from Phytocos (France) under the trade names COMPLEXE AMINCISSANT LP1TM, COMPLEXE AMINCISSANT SGLPTM, EXTRAIT d'ULMAIRE LP1TM, and EXTRAIT d'ULMAIRE SGLPTM.
  • Spiraea ulmaria extract obtained from the flower can be purchased from Indena S.A. (France) under the trade name SWEET SUPEXTRATTM or from Greentech S.A. (France) under the trade names PHYTELENE COMPLEX EGX 250TM, PHYTELENE OF QUEEN MEADOW EG 213 LIQUIDTM, and PHYTELENE OF ULMAIRE EG 213 LIQUIDTM, and SLIMMINGTM.
  • Spiraea ulmaria extract obtained from the root can purchased from Active Organics (USA) under the trade names ACTIPHYTE OF MEADOWSWEET PG50TM, CO ACTIPHYTE OF MEADOWSWEET AJTM, CO ACTIPHYTE OF MEADOWSWEET ALTM, CO ACTIPHYTE OF MEADOWSWEET GLTM, CO ACTIPHYTE OF MEADOWSWEET LIPO OTM, CO ACTIPHYTE OF MEADOWSWEET LIPO RSTM, CO ACTIPHYTE OF MEADOWSWEET LIPO STM, and CO ACTIPHYTE OF MEADOWSWEET LIPO SUNTM.
  • Cystoseira amentacea/Caespitosa Brachycarpa extract a water fraction prepared from Cystoseira amentacea Bory, Cystoseira caespitosa Sauvageau, and Cystoseira brachycarpa var. balearica (Sauvageau) Giaccone, can be purchased from Gelyma (France) or Biosil Technologies (USA) under the trade name SEA HEATHERTM.
  • Hydrolyzed soy protein which is hydrolysate of soy protein derived by acid, enzyme, or other methods of hydrolysis, can be purchased from MGP Ingredients Inc. (USA) under the trade name AQUA PROTM SP, AQUA PROTM SP 15, AQUA PROTM SP 20, and AQUA PROTM SPSF, or from Arch Personal Care Products (USA) under the trade names SOLU-SOYTM 25, SOLU-SOYTM EN-25, SOLU-SOYTM ENSD, or SOLU-SOYTM 25, or from Croda, Inc.
  • Mushroom extract extract obtained from mushrooms, can be purchased from Active Concepts (USA), under the trade names ACB MUSHROOM EXTRACT (POWDER) SMTM, ACB MUSHROOM EXTRACT SMTM, ACB SONGYI MUSHROOM EXTRACTTM, ACB SONGYI MUSHROOM EXTRACT POWDERTM, ABS MUSHROOM EXTRACT BG, or ABS MUSHROOM EXTRACT POWDERTM.
  • ACB MUSHROOM EXTRACT POWDER
  • the inventors also contemplate that other portions of the substrate (e.g., Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, or Mushroom extract) producing the extract can be used in the compositions and methods of the present invention.
  • Non-limiting examples of the other portions include the whole fruit, whole vegetable, whole plant, whole tree, whole bush, seed, peel, fruit, stem, bark, leaf, root, flower, petal, bulb, etc. These other portions are described in the International Cosmetic Ingredient Dictionary Handbook, 12 th Edition (2008), which is incorporated by reference.
  • Additional anti-acne ingredients can also be incorporated in the compositions of the present invention.
  • additional ingredients include salicylic acid, benzoic acid, benzoyl peroxide, and tretinoin. These forms of anti-acne ingredient when used in effective amounts tend to produce dry, flaky, scaly skin and can also irritate the skin.
  • These adverse symptoms can be reduced or prevented when the ingredients are incorporated into the compositions of the present invention. The symptoms can be reduced or prevented in instances where an effective amount (or excess of an effective amount) of such ingredients are used.
  • compositions of the present invention in that the efficacy of the compositions can be increased by use of such skin-caustic ingredients (e.g., salicylic acid, benzoic acid, benzoyl peroxide, and tretinoin) while preventing or reducing the unwanted side-effects produced by the caustic ingredients.
  • skin-caustic ingredients e.g., salicylic acid, benzoic acid, benzoyl peroxide, and tretinoin
  • Oxygen Radical Absorption (or Absorbance) Capacity is an assay that measures the antioxidant activity of an ingredient or composition. In essence, it can quantify the degree and length of time it takes to inhibit the action of an oxidizing agent such as oxygen radicals that are known to cause damage cells (e.g., skin cells).
  • the ORAC value of the compositions of the present invention can be determined by methods known to those of ordinary skill in the art (see U.S. Publication Nos. 2004/0109905 and 2005/0163880; Cao et al. (1993)), all of which are incorporated by reference).
  • the assay described in Cao et al. (1993) measures the ability of antioxidant compounds in test materials to inhibit the decline of B-phycoerythrm (B-PE) fluorescence that is induced by a peroxyl radical generator, AAPH.
  • B-PE B-phycoerythrm
  • compositions of the present invention can include Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, Mushroom extract, an anti-acne ingredient (e.g., salicylic acid, benzoic acid, benzoyl peroxide, tretinoin, etc.), or an additional ingredient, or any combination thereof.
  • Arctium lappa Bodock root extract
  • Epilobium angustifolium Canadian Willowherb
  • Pinus sylvestris bark extract Pinus sylvestris bark extract
  • Ribes nigrum Black Currant
  • compositions can include any number of combinations of additional ingredients described throughout this specification.
  • concentrations of the any ingredient within the compositions can vary.
  • the compositions can comprise, consisting essentially of, or consist of, in their final form, for example, at least about 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.0010%, 0.0011%, 0.0012%, 0.0013%, 0.0014%, 0.0015%, 0.0016%, 0.0017%, 0.0018%, 0.0019%, 0.0020%, 0.0021%, 0.0022%, 0.0023%, 0.0024%, 0.0025%, 0.0026%, 0.0027%, 0.0028%, 0.0029%, 0.0030%, 0.0031%, 0.0032%, 0.0033%, 0.0034%, 0.0035%, 0.0036%, 0.0037%, 0.0038%, 0.0039%, 0.0030%, 0.0031%
  • compositions of the present invention may also include various antioxidants to retard oxidation of one or more components. Additionally, the prevention of the action of microorganisms can be brought about by preservatives such as various antibacterial and antifungal agents, including but not limited to parabens (e.g., methylparabens, propylparabens), chlorobutanol, phenol, sorbic acid, thimerosal or combinations thereof.
  • preservatives such as various antibacterial and antifungal agents, including but not limited to parabens (e.g., methylparabens, propylparabens), chlorobutanol, phenol, sorbic acid, thimerosal or combinations thereof.
  • compositions of the present invention can be incorporated into all types of vehicles.
  • suitable vehicles include emulsions (e.g., water-in-oil, water-in-oil-in-water, oil-in-water, silicone-in-water, water-in-silicone, oil-in-water-in-oil, oil-in-water-in-silicone emulsions), creams, lotions, solutions (both aqueous and hydro-alcoholic), anhydrous bases (such as lipsticks and powders), gels, and ointments or by other method or any combination of the forgoing as would be known to one of ordinary skill in the art (Remington's, 1990).
  • emulsions e.g., water-in-oil, water-in-oil-in-water, oil-in-water, silicone-in-water, water-in-silicone, oil-in-water-in-oil, oil-in-water-in-silicone emulsions
  • creams lotions
  • ingredients identified throughout this specification including but not limited to Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, Mushroom extract, or any combination thereof, or an additional anti-acne ingredient (e.g., salicylic acid, benzoic acid, benzoyl peroxide, tretinoin, etc.), or any combination thereof, can be individually or combinatorially encapsulated for delivery to a target area such as skin.
  • an additional anti-acne ingredient e.g., salicylic acid, benzoic acid, benzoyl peroxide, t
  • Non-limiting examples of encapsulation techniques include the use of liposomes, vesicles, and/or nanoparticles (e.g., biodegradable and non-biodegradable colloidal particles comprising polymeric materials in which the ingredient is trapped, encapsulated, and/or absorbed—examples include nanospheres and nanocapsules) that can be used as delivery vehicles to deliver the ingredient to skin (see, e.g., U.S. Pat. No. 6,387,398; U.S. Pat. No. 6,203,802; U.S. Pat. No. 5,411,744; Kreuter 1998).
  • nanoparticles e.g., biodegradable and non-biodegradable colloidal particles comprising polymeric materials in which the ingredient is trapped, encapsulated, and/or absorbed—examples include nanospheres and nanocapsules
  • composition of the present invention can also be used in many cosmetic products including, but not limited to, sunscreen products, sunless skin tanning products, hair products, finger nail products, moisturizing creams, skin benefit creams and lotions, softeners, day lotions, gels, ointments, foundations, night creams, lipsticks, cleansers, toners, masks, or other known cosmetic products or applications. Additionally, the cosmetic products can be formulated as leave-on or rinse-off products. In certain aspects, the compositions of the present invention are stand-alone products.
  • compositions of the present invention can include additional ingredients such as cosmetic ingredients and pharmaceutical active ingredients. Non-limiting examples of these additional ingredients are described in the following subsections.
  • fragrances artificial and natural
  • dyes and color ingredients e.g., Blue 1, Blue 1 Lake, Red 40, titanium dioxide, D&C blue no. 4, D&C green no. 5, D&C orange no. 4, D&C red no. 17, D&C red no. 33, D&C violet no. 2, D&C yellow no. 10, and D&C yellow no.
  • adsorbents include, e.g., emollients, humectants, film formers, occlusive agents, and agents that affect the natural moisturization mechanisms of the skin), water-repellants, UV absorbers (physical and chemical absorbers such as paraminobenzoic acid (“PABA”) and corresponding PABA derivatives, titanium dioxide, zinc oxide, etc.), essential oils, vitamins (e.g. A, B, C, D, E, and K), trace metals (e.g. zinc, calcium and selenium), anti-irritants (e.g. steroids and non-steroidal anti-inflammatories), botanical extracts (e.g.
  • aloe vera chamomile, cucumber extract, ginkgo biloba , ginseng, and rosemary
  • anti-microbial agents e.g., antioxidants (e.g., BHT and tocopherol), chelating agents (e.g., disodium EDTA and tetrasodium EDTA), preservatives (e.g., methylparaben and propylparaben), pH adjusters (e.g., sodium hydroxide and citric acid), absorbents (e.g., aluminum starch octenylsuccinate, kaolin, corn starch, oat starch, cyclodextrin, talc, and zeolite), skin bleaching and lightening agents (e.g., hydroquinone and niacinamide lactate), humectants (e.g., sorbitol, urea, and manitol), exfoliants, waterproofing agents (e.g., magnesium/alumin
  • UV absorption agents that can be used in combination with the compositions of the present invention include chemical and physical sunblocks.
  • chemical sunblocks that can be used include para-aminobenzoic acid (PABA), PABA esters (glyceryl PABA, amyldimethyl PABA and octyldimethyl PABA), butyl PABA, ethyl PABA, ethyl dihydroxypropyl PABA, benzophenones (oxybenzone, sulisobenzone, benzophenone, and benzophenone-1 through 12), cinnamates (octyl methoxycinnamate, isoamyl p-methoxycinnamate, octylmethoxy cinnamate, cinoxate, diisopropyl methyl cinnamate, DEA-methoxycinnamate, ethyl diisopropylcinnamate, glyceryl octanoate dim
  • Non-limiting examples of moisturizing agents that can be used with the compositions of the present invention include amino acids, chondroitin sulfate, diglycerin, erythritol, fructose, glucose, glycerin, glycerol polymers, glycol, 1,2,6-hexanetriol, honey, hyaluronic acid, hydrogenated honey, hydrogenated starch hydrolysate, inositol, lactitol, maltitol, maltose, mannitol, natural moisturizing factor, PEG-15 butanediol, polyglyceryl sorbitol, salts of pyrollidone carboxylic acid, potassium PCA, propylene glycol, sodium glucuronate, sodium PCA, sorbitol, sucrose, trehalose, urea, and xylitol.
  • acetylated lanolin examples include acetylated lanolin, acetylated lanolin alcohol, alanine, algae extract, aloe barbadensis, aloe - barbadensis extract, aloe barbadensis gel, althea officinalis extract, apricot ( prunus armeniaca ) kernel oil, arginine, arginine aspartate, arnica montana extract, aspartic acid, avocado ( persea gratissima ) oil, barrier sphingolipids, butyl alcohol, beeswax, behenyl alcohol, beta-sitosterol, birch ( betula alba ) bark extract, borage ( borago officinalis ) extract, butcherbroom ( ruscus aculeatus ) extract, butylene glycol, calendula officinalis extract, calendula officinalis oil, candelilla ( euphorbia cerif
  • Non-limiting examples of antioxidants that can be used with the compositions of the present invention include acetyl cysteine, ascorbic acid polypeptide, ascorbyl dipalmitate, ascorbyl methylsilanol pectinate, ascorbyl palmitate, ascorbyl stearate, BHA, BHT, t-butyl hydroquinone, cysteine, cysteine HCl, diamylhydroquinone, di-t-butylhydroquinone, dicetyl thiodipropionate, dioleyl tocopheryl methylsilanol, disodium ascorbyl sulfate, distearyl thiodipropionate, ditridecyl thiodipropionate, dodecyl gallate, erythorbic acid, esters of ascorbic acid, ethyl ferulate, ferulic acid, gallic acid esters, hydroquinone, isoocty
  • compositions of the present invention can include a structuring agent.
  • Structuring agent in certain aspects, assist in providing rheological characteristics to the composition to contribute to the composition's stability.
  • structuring agents can also function as an emulsifier or surfactant.
  • Non-limiting examples of structuring agents include stearic acid, palmitic acid, stearyl alcohol, cetyl alcohol, behenyl alcohol, stearic acid, palmitic acid, the polyethylene glycol ether of stearyl alcohol having an average of about 1 to about 21 ethylene oxide units, the polyethylene glycol ether of cetyl alcohol having an average of about 1 to about 5 ethylene oxide units, and mixtures thereof.
  • the compositions do not include an emulsifier. In other aspects, however, the compositions can include one or more emulsifiers. Emulsifiers can reduce the interfacial tension between phases and improve the formulation and stability of an emulsion.
  • the emulsifiers can be nonionic, cationic, anionic, and zwitterionic emulsifiers (See McCutcheon's (1986); U.S. Pat. Nos. 5,011,681; 4,421,769; 3,755,560).
  • Non-limiting examples include esters of glycerin, esters of propylene glycol, fatty acid esters of polyethylene glycol, fatty acid esters of polypropylene glycol, esters of sorbitol, esters of sorbitan anhydrides, carboxylic acid copolymers, esters and ethers of glucose, ethoxylated ethers, ethoxylated alcohols, alkyl phosphates, polyoxyethylene fatty ether phosphates, fatty acid amides, acyl lactylates, soaps, TEA stearate, DEA oleth-3 phosphate, polyethylene glycol 20 sorbitan monolaurate (polysorbate 20), polyethylene glycol 5 soya sterol, steareth-2, steareth-20, steareth-21, ceteareth-20, PPG-2 methyl glucose ether distearate, ceteth-10, polysorbate 80, cetyl phosphate, potassium cetyl phosphat
  • silicone containing compounds include any member of a family of polymeric products whose molecular backbone is made up of alternating silicon and oxygen atoms with side groups attached to the silicon atoms.
  • silicones can be synthesized into a wide variety of materials. They can vary in consistency from liquid to gel to solids.
  • Non-limiting examples include silicone oils (e.g., volatile and non-volatile oils), gels, and solids.
  • the silicon containing compounds includes a silicone oils such as a polyorganosiloxane.
  • Non-limiting examples of polyorganosiloxanes include dimethicone, cyclomethicone, polysilicone-11, phenyl trimethicone, trimethylsilylamodimethicone, stearoxytrimethylsilane, or mixtures of these and other organosiloxane materials in any given ratio in order to achieve the desired consistency and application characteristics depending upon the intended application (e.g., to a particular area such as the skin, hair, or eyes).
  • a “volatile silicone oil” includes a silicone oil have a low heat of vaporization, i.e. normally less than about 50 cal per gram of silicone oil.
  • Non-limiting examples of volatile silicone oils include: cyclomethicones such as Dow Corning 344 Fluid, Dow Corning 345 Fluid, Dow Corning 244 Fluid, and Dow Corning 245 Fluid, Volatile Silicon 7207 (Union Carbide Corp., Danbury, Conn.); low viscosity dimethicones, i.e. dimethicones having a viscosity of about 50 cst or less (e.g., dimethicones such as Dow Corning 200-0.5 cst Fluid).
  • the Dow Corning Fluids are available from Dow Corning Corporation, Midland, Mich.
  • Cyclomethicone and dimethicone are described in the Third Edition of the CTFA Cosmetic Ingredient Dictionary (incorporated by reference) as cyclic dimethyl polysiloxane compounds and a mixture of fully methylated linear siloxane polymers end-blocked with trimethylsiloxy units, respectively.
  • Other non-limiting volatile silicone oils that can be used in the context of the present invention include those available from General Electric Co., Silicone Products Div., Waterford, N.Y. and SWS Silicones Div. of Stauffer Chemical Co., Adrian, Mich.
  • Essential oils include oils derived from herbs, flowers, trees, and other plants. Such oils are typically present as tiny droplets between the plant's cells, and can be extracted by several method known to those of skill in the art (e.g., steam distilled, enfleurage (i.e., extraction by using fat), maceration, solvent extraction, or mechanical pressing). When these types of oils are exposed to air they tend to evaporate (i.e., a volatile oil). As a result, many essential oils are colorless, but with age they can oxidize and become darker. Essential oils are insoluble in water and are soluble in alcohol, ether, fixed oils (vegetal), and other organic solvents. Typical physical characteristics found in essential oils include boiling points that vary from about 160° to 240° C. and densities ranging from about 0.759 to about 1.096.
  • Essential oils typically are named by the plant from which the oil is found.
  • rose oil or peppermint oil are derived from rose or peppermint plants, respectively.
  • Non-limiting examples of essential oils that can be used in the context of the present invention include sesame oil, macadamia nut oil, tea tree oil, evening primrose oil, Spanish sage oil, Spanish rosemary oil, coriander oil, thyme oil, pimento berries oil, rose oil, anise oil, balsam oil, bergamot oil, rosewood oil, cedar oil, chamomile oil, sage oil, clary sage oil, clove oil, cypress oil, eucalyptus oil, fennel oil, sea fennel oil, frankincense oil, geranium oil, ginger oil, grapefruit oil, jasmine oil, juniper oil, lavender oil, lemon oil, lemongrass oil, lime oil, mandarin oil, marjoram oil, myrrh oil, neroli oil, orange oil, patch
  • Thickening agents include substances which that can increase the viscosity of a composition.
  • Thickeners includes those that can increase the viscosity of a composition without substantially modifying the efficacy of the active ingredient within the composition.
  • Thickeners can also increase the stability of the compositions of the present invention.
  • thickeners include hydrogenated polyisobutene or trihydroxystearin, or a mixture of both.
  • Non-limiting examples of additional thickening agents that can be used in the context of the present invention include carboxylic acid polymers, crosslinked polyacrylate polymers, polyacrylamide polymers, polysaccharides, and gums.
  • carboxylic acid polymers include crosslinked compounds containing one or more monomers derived from acrylic acid, substituted acrylic acids, and salts and esters of these acrylic acids and the substituted acrylic acids, wherein the crosslinking agent contains two or more carbon-carbon double bonds and is derived from a polyhydric alcohol (see U.S. Pat. Nos. 5,087,445; 4,509,949; 2,798,053; CTFA International Cosmetic Ingredient Dictionary, Fourth edition, 1991, pp. 12 and 80).
  • carboxylic acid polymers examples include carbomers, which are homopolymers of acrylic acid crosslinked with allyl ethers of sucrose or pentaerytritol (e.g., CarbopolTM 900 series from B.F. Goodrich).
  • Non-limiting examples of crosslinked polyacrylate polymers include cationic and nonionic polymers. Examples are described in U.S. Pat. Nos. 5,100,660; 4,849,484; 4,835,206; 4,628,078; 4,599,379).
  • Non-limiting examples of polyacrylamide polymers include polyacrylamide, isoparaffin and laureth-7, multi-block copolymers of acrylamides and substituted acrylamides with acrylic acids and substituted acrylic acids.
  • Non-limiting examples of polysaccharides include cellulose, carboxymethyl hydroxyethylcellulose, cellulose acetate propionate carboxylate, hydroxyethylcellulose, hydroxyethyl ethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, methyl hydroxyethylcellulose, microcrystalline cellulose, sodium cellulose sulfate, and mixtures thereof.
  • alkyl substituted cellulose where the hydroxy groups of the cellulose polymer is hydroxyalkylated (preferably hydroxy ethylated or hydroxypropylated) to form a hydroxyalkylated cellulose which is then further modified with a C 10 -C 30 straight chain or branched chain alkyl group through an ether linkage.
  • these polymers are ethers of C 10 -C 30 straight or branched chain alcohols with hydroxyalkylcelluloses.
  • Other useful polysaccharides include scleroglucans comprising a linear chain of (1-3) linked glucose units with a (1-6) linked glucose every three unit.
  • Non-limiting examples of gums that can be used with the present invention include acacia , agar, algin, alginic acid, ammonium alginate, amylopectin, calcium alginate, calcium carrageenan, carnitine, carrageenan, dextrin, gelatin, gellan gum, guar gum, guar hydroxypropyltrimonium chloride, hectorite, hyaluroinic acid, hydrated silica, hydroxypropyl chitosan, hydroxypropyl guar, karaya gum, kelp, locust bean gum, natto gum, potassium alginate, potassium carrageenan, propylene glycol alginate, sclerotium gum, sodium carboyxmethyl dextran, sodium carrageenan, tragacanth gum, xanthan gum, and mixtures thereof.
  • Non-limiting examples of preservatives that can be used in the context of the present invention include quaternary ammonium preservatives such as polyquaternium-1 and benzalkonium halides (e.g., benzalkonium chloride (“BAC”) and benzalkonium bromide), parabens (e.g., methylparabens and propylparabens), phenoxyethanol, benzyl alcohol, chlorobutanol, phenol, sorbic acid, thimerosal or combinations thereof.
  • quaternary ammonium preservatives such as polyquaternium-1 and benzalkonium halides (e.g., benzalkonium chloride (“BAC”) and benzalkonium bromide), parabens (e.g., methylparabens and propylparabens), phenoxyethanol, benzyl alcohol, chlorobutanol, phenol, sorbic acid, thimerosal or combinations thereof.
  • Pharmaceutical active agents are also contemplated as being useful with the compositions of the present invention.
  • Non-limiting examples of pharmaceutical active agents include agents used to treat rosacea, analgesics, anesthetics, anorectals, antihistamines, anti-inflammatory agents including non-steroidal anti-inflammatory drugs, antibiotics, antifungals, antivirals, antimicrobials, anti-cancer actives, scabicides, pediculicides, antineoplastics, antiperspirants, antipruritics, antipsoriatic agents, antiseborrheic agents, biologically active proteins and peptides, burn treatment agents, cauterizing agents, depigmenting agents, depilatories, diaper rash treatment agents, enzymes, hair growth stimulants, hair growth retardants including DFMO and its salts and analogs, hemostatics, kerotolytics, canker sore treatment agents, cold sore treatment agents, dental and periodontal treatment agents, photosensitizing actives, skin protectant/barrier agents,
  • Kits are also contemplated as being used in certain aspects of the present invention.
  • compositions of the present invention can be included in a kit.
  • a kit can include a container.
  • Containers can include a bottle, a metal tube, a laminate tube, a plastic tube, a dispenser, a pressurized container, a barrier container, a package, a compartment, a lipstick container, a compact container, cosmetic pans that can hold cosmetic compositions, or other types of containers such as injection or blow-molded plastic containers into which the dispersions or compositions or desired bottles, dispensers, or packages are retained.
  • the kit and/or container can include indicia on its surface.
  • the indicia for example, can be a word, a phrase, an abbreviation, a picture, or a symbol.
  • the containers can dispense a pre-determined amount of the composition.
  • the container can be squeezed (e.g., metal, laminate, or plastic tube) to dispense a desired amount of the composition.
  • the composition can be dispensed as a spray, an aerosol, a liquid, a fluid, or a semi-solid.
  • the containers can have spray, pump, or squeeze mechanisms.
  • a kit can also include instructions for employing the kit components as well the use of any other compositions included in the container. Instructions can include an explanation of how to apply, use, and maintain the compositions.
  • compositions of the present invention are described in Tables 1 and 2. These compositions can be used as vehicles to test the efficacy of the active ingredients to treat skin.
  • the active ingredients can include Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, Mushroom extract, or an anti-acne ingredient (e.g., salicylic acid, benzylic acid, benzoyl peroxide, tretinoin, etc.) or any combination thereof.
  • an anti-acne ingredient e.g., salicylic acid, benzylic acid, benzoyl peroxide, tretinoin, etc.
  • the total amount of active ingredients in the Table 1 formulation is 2% w/w, it is contemplated that the amount of active ingredients can be increased or decreased to achieve a desired result, where the water amount can be increased/decreased accordingly (e.g., q.s.).
  • the active ingredients can include Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, Mushroom extract, or an anti-acne ingredient (e.g., salicylic acid, benzylic acid, benzoyl peroxide, tretinoin, etc.) or any combination thereof.
  • Arctium lappa Bodock root extract
  • Epilobium angustifolium Canadian Willowherb
  • Pinus sylvestris bark extract Pinus sylvestris bark extract
  • Ribes nigrum Black Currant
  • the total amount of active ingredients in the Table 1 formulation is 2% w/w, it is contemplated that the amount of active ingredients can be increased or decreased to achieve a desired result, where the water amount can be increased/decreased accordingly (e.g., q.s.).
  • Non-limiting skin product formulations of the present invention is described in Tables 3-9.
  • the compositions can be made by any known methods in the art. For instance, simple mixing of the ingredients into a container can be used. Further, it is contemplated that additional ingredients can be added to the product formulations, listed ingredients can be replaced, and/or listed ingredients can be removed. The concentration ranges of the ingredients can be modified.
  • the increased bacterial lode within acne lesions draws inflammatory cells into the area stimulated by the increased expression of pro-inflammatory cytokines. As acne lesions emerge, inflammation occurs as the skin attempts to heal itself Overall, redness of the skin surrounding the acne lesion is intensified by the release of pro-inflammatory cytokines.
  • Human adult epidermal keratinocytes were cultured at 37° C. and 5.0% CO 2 in standard growth medium. At 70-80% confluent, cells were treated with plant extracts for 5 h in the presence or absence of phorbol myristyl acetate. Following, all media was collected and assayed for inflammatory cytokine production analysis using the FaST Quant Kit—Following blocking, supernatant was added to each array. Each array contains triplicate spots for each cytokine. Arrays were incubated for 3 hours and treated with an antibody cocktail, containing one biotinylated antibody corresponding to each of the arrayed capture antibodies. Arrays were incubated for 1 h and incubated with a streptavidin-Cy5.
  • Arrays were imaged on a Perkin-Elmer ScanArray 4000 confocal fluorescent imaging system. Array images were analyzed using Imaging Research ArrayVision software. Spot intensities were determined by subtracting background signal. Spot replicates were averaged and compared to the appropriate controls. Data was calculated as a percent change from appropriate controls.
  • FIG. 1 A summary of the results is in FIG. 1 .
  • Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, and Cystoseira amentacea/Caespitosa Brachycarpa extract can act to reduce the expression of known inflammatory cytokines in human epidermal keratinocytes induced by chemical treatment.
  • these data support the ability of these botanical to reduce the potential for skin irritation associated with acne prone skin.
  • compositions or active ingredients within a given composition of the present inventions can be determined by methods known to those of ordinary skill in the art.
  • the following are non-limiting procedures that can be used in the context of the present invention. It should be recognized that other testing procedures can be used, including, for example, objective and subjective procedures.
  • the active ingredients e.g., Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, or an anti-acne ingredient (e.g., salicylic acid, benzylic acid, benzoyl peroxide, tretinoin, etc.) or any combination thereof, can be tested for their skin efficacy by using the composition vehicles identified in Tables 1 and 2. As noted in these Tables, the active ingredients and concentration ranges can vary.
  • Acne treatment can be visually monitored by applying a treatment composition to acne associated symptoms (e.g., open or closed comedones, papules (pimples), pustules, nodulocystic lesions, etc.) and inspecting the symptom over a period of time (e.g., 1, 2, 3, 4, 5, 6, days, 1, 2, 3, 4, weeks, 1, 2, 3, 4, months, etc.).
  • acne associated symptoms e.g., open or closed comedones, papules (pimples), pustules, nodulocystic lesions, etc.
  • Acne prevention can be visually monitored by applying a prevention composition to skin susceptible of exhibiting an acne associated symptom (e.g., chin, cheek, eye, nose, forehead, etc., skin of a child, teenage, young adult, adult, or senior citizen) and inspecting the skin over a period of time.
  • the existence of symptoms associated with acne treatment e.g., dry, flaky, or scaly skin or irritated skin
  • Skin moisture/hydration can be measured by using impedance measurements with the Nova Dermal Phase Meter.
  • the impedance meter measures changes in skin moisture content.
  • the outer layer of the skin has distinct electrical properties. When skin is dry it conducts electricity very poorly. As it becomes more hydrated increasing conductivity results. Consequently, changes in skin impedance (related to conductivity) can be used to assess changes in skin hydration.
  • the unit can be calibrated according to instrument instructions for each testing day. A notation of temperature and relative humidity can also be made. Subjects can be evaluated as follows: prior to measurement they can equilibrate in a room with defined humidity (e.g., 30-50%) and temperature (e.g., 68-72C).
  • T5 setting can be used on the impedance meter which averages the impedance values of every five seconds application to the face. Changes can be reported with statistical variance and significance.
  • Skin clarity and the reduction in freckles and age spots can be evaluated using a Minolta Chromometer. Changes in skin color can be assessed to determine irritation potential due to product treatment using the a* values of the Minolta Chroma Meter. The a* value measures changes in skin color in the red region. This is used to determine whether a composition is inducing irritation. The measurements can be made on each side of the face and averaged, as left and right facial values. Skin clarity can also be measured using the Minolta Meter. The measurement is a combination of the a*, b, and L values of the Minolta Meter and is related to skin brightness, and correlates well with skin smoothness and hydration. Skin reading is taken as above. In one non-limiting aspect, skin clarity can be described as L/C where C is chroma and is defined as (a 2 +b 2 ) 1/2 .
  • Skin dryness, surface fine lines, skin smoothness, and skin tone can be evaluated with clinical grading techniques.
  • clinical grading of skin dryness can be determined by a five point standard Kligman Scale: (0) skin is soft and moist; (1) skin appears normal with no visible dryness; (2) skin feels slightly dry to the touch with no visible flaking; (3) skin feels dry, tough, and has a whitish appearance with some scaling; and (4) skin feels very dry, rough, and has a whitish appearance with scaling. Evaluations can be made independently by two clinicians and averaged.
  • Clinical grading of skin tone can be performed via a ten point analog numerical scale: (10) even skin of uniform, pinkish brown color. No dark, erythremic, or scaly patches upon examination with a hand held magnifying lens. Microtexture of the skin very uniform upon touch; (7) even skin tone observed without magnification. No scaly areas, but slight discolorations either due to pigmentation or erythema. No discolorations more than 1 cm in diameter; (4) both skin discoloration and uneven texture easily noticeable. Slight scaliness. Skin rough to the touch in some areas; and (1) uneven skin coloration and texture. Numerous areas of scaliness and discoloration, either hypopigmented, erythremic or dark spots. Large areas of uneven color more than 1 cm in diameter. Evaluations were made independently by two clinicians and averaged.
  • Clinical grading of skin smoothness can be analyzed via a ten point analog numerical scale: (10) smooth, skin is moist and glistening, no resistance upon dragging finger across surface; (7) somewhat smooth, slight resistance; (4) rough, visibly altered, friction upon rubbing; and (1) rough, flaky, uneven surface. Evaluations were made independently by two clinicians and averaged.
  • Skin smoothness and wrinkle reduction can also be assessed visually by using the methods disclosed in Packman et al. (1978). For example, at each subject visit, the depth, shallowness and the total number of superficial facial lines (SFLs) of each subject can be carefully scored and recorded. A numerical score was obtained by multiplying a number factor times a depth/width/length factor. Scores are obtained for the eye area and mouth area (left and right sides) and added together as the total wrinkle score.
  • SFLs superficial facial lines
  • Skin firmness can be measured using a Hargens ballistometer, a device that evaluates the elasticity and firmness of the skin by dropping a small body onto the skin and recording its first two rebound peaks.
  • the ballistometry is a small lightweight probe with a relatively blunt tip (4 square mm-contact area) was used. The probe penetrates slightly into the skin and results in measurements that are dependent upon the properties of the outer layers of the skin, including the stratum corneum and outer epidermis and some of the dermal layers.
  • Skin softness/suppleness can be evaluated using the Gas Bearing Electrodynamometer, an instrument that measures the stress/strain properties of the skin.
  • the viscoelastic properties of skin correlate with skin moisturization. Measurements can be obtained on the predetermined site on the cheek area by attaching the probe to the skin surface with double-stick tape. A force of approximately 3.5 gm can be applied parallel to the skin surface and the skin displacement is accurately measured. Skin suppleness can then be calculated and is expressed as DSR (Dynamic Spring Rate in gm/mm).
  • DSR Dynamic Spring Rate in gm/mm
  • the appearance of lines and wrinkles on the skin can be evaluated using replicas, which is the impression of the skin's surface. Silicone rubber like material can be used.
  • the replica can be analyzed by image analysis. Changes in the visibility of lines and wrinkles can be objectively quantified via the taking of silicon replicas form the subjects' face and analyzing the replicas image using a computer image analysis system. Replicas can be taken from the eye area and the neck area, and photographed with a digital camera using a low angle incidence lighting. The digital images can be analyzed with an image processing program and the are of the replicas covered by wrinkles or fine lines was determined.
  • the surface contour of the skin can be measured by using the profilometer/Stylus method. This includes either shining a light or dragging a stylus across the replica surface.
  • the vertical displacement of the stylus can be fed into a computer via a distance transducer, and after scanning a fixed length of replica a cross-sectional analysis of skin profile can be generated as a two-dimensional curve. This scan can be repeated any number of times along a fix axis to generate a simulated 3-D picture of the skin.
  • Ten random sections of the replicas using the stylus technique can be obtained and combined to generate average values.
  • the values of interest include Ra which is the arithmetic mean of all roughness (height) values computed by integrating the profile height relative to the mean profile height.
  • the efficacy of the compositions of the present invention can be evaluated by using a skin analog, such as, for example, MELANODERMTM.
  • a skin analog such as, for example, MELANODERMTM.
  • Melanocytes one of the cells in the skin analog, stain positively when exposed to L-dihydroxyphenyl alanine (L-DOPA), a precursor of melanin.
  • L-DOPA L-dihydroxyphenyl alanine
  • the skin analog, MELANODERMTM can be treated with a variety of bases containing the compositions and whitening agents of the present invention or with the base alone as a control. Alternatively, an untreated sample of the skin analog can be used as a control.
  • compositions and/or methods disclosed and claimed in this specification can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of particular embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

Abstract

Disclosed is a topical skin care composition and corresponding methods for their use comprising Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, or Cystoseira amentacea/Caespitosa Brachycarpa extract, or any combination thereof.

Description

CROSS REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of U.S. Provisional Application Ser. No. 61/173,042, filed Apr. 27, 2009. The contents of the referenced application is incorporated by reference.
BACKGROUND OF THE INVENTION
A. Field of the Invention
The present invention relates generally to compositions that include botanical extracts that can be used to reduce the redness associated with acne lesions, improve skin clarity through dermal remodeling, and protect the skin from additional acne breakouts. The compositions of the present invention can also be used to treat or prevent a wide variety of skin conditions. In particular, the present invention concerns topical skin care compositions that include Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, or Mushroom extract, or any combination thereof. In particular aspects, the composition includes a combination of Epilobium angustifolium (Canadian Willowherb) extract, Arctium lappa (Burdock) root extract, and Cystoseira amentacea/Caespitosa Brachycarpa extract.
B. Description of Related Art
Salicylic acid, benzoic acid, benzoyl peroxide, and tretinoin are known anti-acne ingredients. Problems/side effects associated with these ingredients include dry skin, scaly skin, and flaky skin. They can also irritate the skin, which causes the skin to appear red and feel like it is burning. Such irritation adds to the already painful sensation associated with the presence of acne on the skin.
SUMMARY OF THE INVENTION
The present invention overcomes deficiencies in the art by providing anti-acne compositions that can treat, reduce, or prevent the appearance of the signs of acne on skin (e.g., comedones, papules, pustules, nodulocystic lesions, skin redness, etc.). These compositions can include Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, or Mushroom extract, or any combination thereof. In particular aspects, the composition includes a combination of Epilobium angustifolium (Canadian Willowherb) extract, Arctium lappa (Burdock) root extract, and Cystoseira amentacea/Caespitosa Brachycarpa extract. In other aspects, the combination of ingredients can be Ribes nigrum (Black curant) leaf extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, hydrolyzed soy protein, Epilobium angustifolium (Canadian Willowherb) extract, and Arctium lappa (Burdock) root extract. In even a more particular aspect, the combination of ingredients can be Ribes nigrum (Black curant) leaf extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, hydrolyzed soy protein, Epilobium angustifolium (Canadian Willowherb) extract, Arctium lappa (Burdock) root extract, navy bean extract, and mushroom extract.
The compositions can also include an added benefit of reducing or preventing the appearance of dry, scaly, flaky skin and skin irritation. That is, the compositions of the present invention can reduce, prevent, or treat the signs of acne on skin while also reducing or preventing or avoiding side-effects such as dry, scaly, flaky skin and skin irritation. These side-effects can be reduced or prevented or avoided even if anti-acne ingredients that are known to cause such side-effects (e.g., salicylic acid, benzoic acid, benzoyl peroxide, tretinoin, etc.) are incorporated into the compositions of the present invention at effective amounts.
As noted above, the compositions of the present invention can include Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Soy extract, Navy bean extract, or Mushroom extract, or any one of, any combination of, or all of such ingredients. Further, as shown in the figures and examples (which are incorporated into this section by reference), the inventors have discovered that the combination of Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, and Cystoseira amentacea/Caespitosa Brachycarpa extract produce synergistic and complimentary effects that are beneficial to skin and to treating or preventing acne. The compositions can also include other anti-acne ingredients, even those known to cause undesirable side-effects such as dry, flaky, scaly skin or skin irritation (e.g., salicylic acid, benzoic acid, benzoyl peroxide, tretinoin etc.).
In certain embodiments, the compositions are formulated into topical skin care compositions. The compositions can be cosmetic compositions. In other aspects, the compositions can be included in a cosmetic vehicle. Non-limiting examples of cosmetic vehicles are disclosed in other sections of this specification and are known to those of skill in the art. Examples of cosmetic vehicles include emulsions (e.g., oil-in-water and water-in-oil emulsions), creams, lotions, solutions (e.g., aqueous or hydro-alcoholic solutions), anhydrous bases (e.g., lipstick or a powder), gels, and ointments. In other non-limiting embodiments, the compositions of the present invention can be included in anti-aging, cleansing, or moisturizing products. The compositions can also be formulated for topical skin application at least 1, 2, 3, 4, 5, 6, 7, or more times a day during use. In other aspects of the present invention, compositions can be storage stable or color stable, or both. It is also contemplated that the viscosity of the composition can be selected to achieve a desired result (e.g., depending on the type of composition desired, the viscosity of such composition can be from about 1 cps to well over 1 million cps or any range or integer derivable therein (e.g., 2 cps, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200000, 300000, 400000, 500000, 600000, 700000, 800000, 900000, 1000000 cps, etc., as measured on a Brookfield Viscometer using a TC spindle at 2.5 rpm at 25° C.). The compositions in non-limiting aspects can have a pH of about 6 to about 9. In other aspects, the pH can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14. In other aspects, the compositions can be sunscreens having a sun protection factor (SPF) of 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or more.
In particular aspects, the compositions can be oil-free, substantially anhydrous, and/or anhydrous. Other aspects include compositions having water.
The compositions of the present invention can include from about 0.001% to about 50%, by weight, of Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, or Mushroom extract, or any combination thereof. It should be recognized, however, that the amount of such ingredients within a composition can be modified below, within, or above this range based on the desired results. Therefore, the amount of such ingredients can include less than 0.0001%. In other aspects, the compositions can include 0.0001, 0.0002 . . . 0.002, 0.003, 0.004 . . . 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 95, 96, 97, 98, 99%, or more or, or any range derivable therein, by weight or volume of Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, or Mushroom extract, or any combination thereof. In certain aspects, the composition can include a dermatologically acceptable vehicle or carrier. Such vehicle or carrier can include any one of, any combination of, or all of the following ingredients: water; salicylic acid or benzoyl peroxide or a combination thereof; phenoxyethanol; butylene glycol; citric acid; propylene glycol; methylparaben or propylparaben or a combination thereof glycerin; chlorphenesin; and/or sodium metabisulfite.
The compositions of the present invention can also be modified to have a desired oxygen radical absorbance capacity (ORAC) value. In certain non-limiting aspects, the compositions of the present invention can be modified to have an ORAC value per mg of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 95, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 15000, 20000, 30000, 50000, 100000 or more or any range derivable therein.
In other non-limiting aspects of the present invention, the compositions can further include a vitamin, a mineral, an essential fatty acid, an amino acid, a flavonoid, and/or a protein, or a combination thereof. Non-limiting examples of vitamins include the B vitamins (e.g., B1, B2, B6, B12, niacin, folic acid, biotin, and pantothenic acid), vitamin C, vitamin D, vitamin E (e.g., tocopherol or tocopheryl acetate), vitamin A (e.g., palmitate, retinyl palmitate, or retinoic acid), and vitamin K. Non-limiting examples of minerals include iron, potassium, phosphorus, magnesium, manganese, selenium, and calcium. Non-limiting examples of essential fatty acids include Omega 3 (linolenic acid), Omega 6 (linoleic acid) and Omega 9 (oleic acid) essential fatty acid, or a combination thereof. Non-limiting examples of amino acids include essential amino acids (e.g., lysine, leucine, isoleucine, methionine, phenylalanine, threonine, tryptophan, valine, histidine, or arginine) and non-essential amino acids (e.g., serine, asparagine, glutamine, aspartic acid, glutamic acid, alanine, tyrosine, cysteine, glycine, or proline). Non-limiting examples of flavonoids include anthocyanin compounds (e.g., cyanidin-3-glucoside and cyanidin-3-rutinoside).
The compositions can include a triglyceride, a preservative, an essential oil, a UV absorption ingredient, and/or additional ingredients described in the specification and known in the art, and any combination thereof. Non-limiting examples of triglycerides include small, medium, and large chain triglycerides. Non-limiting examples of preservatives include methylparaben, propylparaben, or a mixture of methylparaben and propylparaben. Non-limiting examples of essential oils are those described in the specification and those known to a person of ordinary skill in the art. Examples include sesame oil, macadamia nut oil, tea tree oil, evening primrose oil, Spanish sage oil, Spanish rosemary oil, Coriander oil, Thyme oil, or Pimento berries oil. Non limiting examples of UV absorption ingredients include dibenzoylmethane derivatives (e.g., avobenzone), octocrylene, oxybenzone, homosalate, octisalate, octyl methoxycinnamate, ecamsule, titanium dioxide, zinc oxide, etc., and others described in the specification and known to those in the art, and any combination thereof.
Also disclosed is a method of treating or preventing a skin condition comprising topical application of a composition comprising Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, or Mushroom extract, or any combination thereof, wherein the topical application of the composition treats the skin condition. The method can include topical application of the composition to a portion of skin in need of such composition (e.g., skin having a skin condition), wherein topical application reduces or prevents the skin condition when compared to skin that has a skin condition and that has not been treated with the composition. Non-limiting examples of skin conditions include acne, symptoms associated with acne (e.g., presence of open or closed comedones, papules, pustules, nodulocystic lesions, skin redness, etc.), pruritus, spider veins, lentigo, age spots, senile purpura, keratosis, melasma, blotches, fine lines or wrinkles, nodules, sun damaged skin, dermatitis (including, but not limited to seborrheic dermatitis, nummular dermatitis, contact dermatitis, atopic dermatitis, exfoliative dermatitis, perioral dermatitis, and stasis dermatitis), psoriasis, folliculitis, rosacea, impetigo, erysipelas, erythrasma, eczema, and other inflammatory skin conditions. In certain non-limiting aspects, the skin condition can be caused by exposure to UV light, age, irradiation, chronic sun exposure, environmental pollutants, air pollution, wind, cold, heat, chemicals, disease pathologies, smoking, or lack of nutrition. The skin can be facial skin or non-facial skin (e.g., arms, legs, hands, chest, back, feet, etc.). The method can further comprise identifying a person in need of skin treatment. The person can be a male or female. The age of the person can be at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or more years old, or any range derivable therein. The method can also include topically applying an amount effective to: increase the stratum corneum turnover rate of the skin; increase collagen synthesis in fibroblasts; increase cellular anti-oxidant defense mechanisms (e.g., exogenous additions of anti-oxidants can bolster, replenish, or prevent the loss of cellular antioxidants such as catalase and glutathione in skin cells (e.g., keratinocytes, melanocytes, langerhans cells, etc.) which will reduce or prevent oxidative damage to the skin, cellular, proteins, and lipids); inhibit melanin production in melanocytes; reduce or prevent oxidative damage to skin (including reducing the amount lipid peroxides and/or protein oxidation in the skin).
In certain embodiments, compositions of the present invention can decrease the amount of internal oxidation and/or external oxidative damage in a cell. In other aspects, the compositions can increase collagen synthesis in a cell. The compositions can also reduce skin inflammation, such as by reducing inflammatory cytokine production in a cell. Non-limiting examples of such cells include human epidermal keratinocyte, human fibroblast dermal cell, human melanocytes, three dimensional human cell-derived in vitro tissue equivalents comprising human keratinocytes, human fibroblasts, or human melanocytes, or any combination thereof (e.g., combination of human keratinocytes and human fibroblasts or a combination of human keratinocytes and human melanocytes).
Also disclosed is a method of reducing side-effects associated with topical application of anti-acne agents to skin. The method can include incorporating botanical extracts selected from the group consisting of Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, or Mushroom extract, or any combination thereof, into a topical anti-acne formulation which includes an anti-acne agent known to cause side-effects, wherein the addition of the botanical extract into the composition reduces or prevents the side-effects to the skin. The anti-acne agent can be salicylic acid, benzoic acid, benzoyl peroxide, tretinoin, etc. The side-effect can be dry skin, scaly skin, flaky skin, or skin irritation.
In yet another embodiment, the compositions of the present invention can also be used to reduce side-effects associated with topical application of a pharmaceutical ingredient to skin. The method can include incorporating botanical extracts selected from the group consisting of Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, or Mushroom extract, or any combination thereof, or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or all 10 of the aforementioned ingredients, into a topical skin formulation which includes a pharmaceutical ingredient known to cause side-effects, wherein the addition of the botanical extract into the composition reduces or prevents the side-effects to the skin. In particular aspects, the composition includes Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, and Cystoseira amentacea/Caespitosa Brachycarpa extract.
The pharmaceutical ingredient can be an ingredient selected from the group consisting of agents used to treat rosacea, analgesics, anesthetics, anorectals, antihistamines, anti-inflammatory agents including non-steroidal anti-inflammatory drugs, antibiotics, antifungals, antivirals, antimicrobials, anti-cancer actives, scabicides, pediculicides, antineoplastics, antiperspirants, antipruritics, antipsoriatic agents, antiseborrheic agents, biologically active proteins and peptides, burn treatment agents, cauterizing agents, depigmenting agents, depilatories, diaper rash treatment agents, enzymes, hair growth stimulants, hair growth retardants including DFMO and its salts and analogs, hemostatics, kerotolytics, canker sore treatment agents, cold sore treatment agents, dental and periodontal treatment agents, photosensitizing actives, skin protectant/barrier agents, steroids including hormones and corticosteroids, sunburn treatment agents, sunscreens, transdermal actives, nasal actives, vaginal actives, wart treatment agents, wound treatment agents, or wound healing agents.
Also disclosed is a method of lightening skin or evening skin tone comprising applying the compositions of the present invention to the skin. The method can further comprise identify a person in need of lightening skin or evening skin tone. The methods can further include inhibiting melanogenesis in a skin cell, inhibiting tyrosinase or tyrosinase synthesis in a skin cell, or inhibiting melanin transport to keratinocytes in a skin cell. The composition can act as an alpha melanin stimulatory hormone antagonist. The composition can even out pigmentation of the skin. In non-limiting aspect, lightening skin can include reducing the appearance of an age spot, a skin discoloration, or a freckle by topical application of the composition to skin having an age spot, skin discoloration, a freckle, etc.
Also disclosed is a method of treating hyperpigmentation comprising applying the compositions of the present invention to the skin. The method can also comprise identifying a person in need of treating hyperpigmentation. Additional methods contemplated by the inventor include methods for reducing the appearance of an age spot, a skin discoloration, or a freckle, reducing or preventing the appearance of fine lines or wrinkles in skin, or increasing the firmness of skin.
Also disclosed is a method of treating erythema or reducing the appearance of symptoms associated with erythema, sensitive skin, or inflamed skin, comprising topically to erythemic, sensitive, or inflamed skin any one of the compositions of disclosed throughout this specification. In particular embodiments, the composition can include Arctium lappa root extract, Epilobium angustifolium extract, or Cystoseira amentacea/Caespitosa Brachycarpa extract or any combination thereof. In particular instances, the erythema can be caused by acne or an acne lesion (e.g., a comedone, a papule, a pustule, or a nodulocystic lesion on the skin). In other instances, the erythema can be caused by skin sunburn, electrical treatments of skin, skin burns, contact allergies, systemic allergies, skin toxicity, exercise, insect stings, bacterial infection, viral infection, fungal infection, protozoa infection, massage, or windburn.
Compositions comprising Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, or Mushroom extract, or any combination thereof, can produce synergistic effects. For example, such ingredients can work together synergistically to produce effects that exceed the effects of what would be expected if the extracts were used in separate compositions. Non-limiting synergistic effects include treating or preventing acne and symptoms associated with the same, while also preventing, reducing, or avoiding side-effects such as dry, flaky, scaly skin or skin irritation.
Compositions comprising Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, or Mushroom extract, or any combination thereof, can also act in a complementary fashion. For example, such ingredients can be used to treat or prevent acne, treat, prevent, or reduce the appearance of the signs of acne on skin, and reduce, prevent, avoid skin dryness, scaliness, flakiness, or skin irritation, and vice-versa.
Also contemplated are kits that includes the compositions of the present invention. In certain embodiments, the composition is comprised in a container. The container can be a bottle, dispenser, or package. The container can dispense a pre-determined amount of the composition. In certain aspects, the compositions is dispensed in a spray, dollop, or liquid. The container can include indicia on its surface. The indicia can be a word, an abbreviation, a picture, or a symbol.
Also contemplated is a product comprising a composition of the present invention. In non-limiting aspects, the product can be a cosmetic product. The cosmetic product can be those described in other sections of this specification or those known to a person of skill in the art. Non-limiting examples of products include a moisturizer, a cream, a lotion, a skin softener, a foundation, a night cream, a lipstick, a cleanser, a toner, a sunscreen, a mask, or an anti-aging product.
It is also contemplated that compositions of the present invention can be included into food-based products (e.g., beverages, fortified water, energy drinks, nutritional drinks, solid foods, vitamins, supplements, etc.) and pharmaceutical products (e.g., pills, injectible solutions, drugs, etc.). “Supplements” can include vitamins, minerals, herbs or other botanicals, amino acids, enzymes and metabolites. Such supplements are suitable for oral consumption and can be administered orally.
The compositions and methods for their use can “comprise,” “consist essentially of,” or “consist of” any of the ingredients disclosed throughout the specification.
It is contemplated that any embodiment discussed in this specification can be implemented with respect to any method or composition of the invention, and vice versa. Furthermore, compositions of the invention can be used to achieve methods of the invention.
In one embodiment, compositions of the present invention can be pharmaceutically or cosmetically elegant. “Pharmaceutically elegant” and/or “cosmetically elegant” describes a composition that has particular tactile properties which feel pleasant on the skin (e.g., compositions that are not too watery or greasy, compositions that have a silky texture, compositions that are non-tacky or sticky, etc.). Pharmaceutically or cosmetically elegant can also relate to the creaminess or lubricity properties of the composition or to the moisture retaining properties of the composition.
“Topical application” means to apply or spread a composition onto the surface of keratinous tissue. “Topical skin composition” includes compositions suitable for topical application on keratinous tissue. Such compositions are typically dermatologically-acceptable in that they do not have undue toxicity, incompatibility, instability, allergic response, and the like, when applied to skin. Topical skin care compositions of the present invention can have a selected viscosity to avoid significant dripping or pooling after application to skin.
“Keratinous tissue” includes keratin-containing layers disposed as the outermost protective covering of mammals and includes, but is not limited to, skin, hair and nails.
A “non-volatile oil” includes those substance that will not evaporate at ordinary or room temperature.
The terms “mixture,” “mix,” and “mixing” or any variants of these terms, when used in the claims and/or specification includes, stirring, blending, dispersing, milling, homogenizing, and other similar methods. The mixing of the components or ingredients of the disclosed compositions can form into a solution. In other embodiments, the mixtures may not form a solution. The ingredients/components can also exist as undissolved colloidal suspensions.
The term “about” or “approximately” are defined as being close to as understood by one of ordinary skill in the art, and in one non-limiting embodiment the terms are defined to be within 10%, preferably within 5%, more preferably within 1%, and most preferably within 0.5%.
The term “substantially” and its variations are defined as being largely but not necessarily wholly what is specified as understood by one of ordinary skill in the art, and in one non-limiting embodiment substantially refers to ranges within 10%, within 5%, within 1%, or within 0.5%.
The terms “inhibiting” or “reducing” or “preventing” or “avoiding” or any variation of these terms, when used in the claims and/or the specification includes any measurable decrease or complete inhibition to achieve a desired result.
The term “effective,” as that term is used in the specification and/or claims, means adequate to accomplish a desired, expected, or intended result.
The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”
The use of the term “or” in the claims is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and/or.”
As used in this specification and claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the examples, while indicating specific embodiments of the invention, are given by way of illustration only. Additionally, it is contemplated that changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented below.
FIG. 1 Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, and Cystoseira amentacea/Caespitosa Brachycarpa extract, reduce the expression of proinflamattory cytokines IL-8, IL-2, and TNF-α in human epidermal keratinocytes.
DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
Acne is commonly referred to as a disorder of the pilosebaceuous unit, which includes the hair follicle, seabaceous gland, and sebaceous duct. Propionibacterium acnes (“P. acnes”), an anaerobic bacteria, is present in all types of human skin and is part of the skin's natural sebum maintenance system.
Sebaceous glands produce sebum, which is excreted through the sebaceous duct and travels up the follicle. The sebum mixes with common skin bacteria (including P. acnes) and dead skin cells that have been shed from the lining of the follicle. While this process is normal, the presence of extra sebum (note that sebum production can increase when stimulated by hormones such as androgens) can increase the possibility that the pilosebaceuous unit becomes plugged/clogged/obstructed. The end result of this is oftentimes an inflammatory response, which can lead to pimples becoming red, swollen, and painful.
The outward signs of acne on the skin has been categorized as noninflammatory and inflammatory acne. Noninflammatory acne typically includes the presence of whiteheads and blackheads (respectively referred to as closed and open comedones). These comedones are compact masses of keratin, sebum, and bacteria, which dilate the follicular duct. A comedone forms when a follicle or sebaceous duct is plugged/clogged/obstructed. Inflammatory acne has been characterized by papules (pimples), pustules, and nodulocystic lesions which can lead to scarring of the skin.
The compositions of the present invention provide for an effective option for treating, reducing, or preventing acne and its associated symptoms (e.g., presence of open and closed comedones, papules, pustules, nodulocystic lesions, skin redness, etc.) by providing topical skin compositions which include natural botanical extracts such as Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, or Mushroom extract, or any combination thereof. The compositions of the present invention also provide a solution to the above-described problems associated with popular anti-acne agents such as salicylic acid, benzoic acid, benzoyl peroxide, and tretinoin. These types of caustic anti-acne agents can be incorporated into compositions of the present invention at effective amounts while avoiding or substantially reducing the unwanted side-effects. Another advantage is that higher levels of such caustic anti-acne agents can be used, thereby increasing the composition's overall anti-acne effectiveness and the unsightly symptom associated with skin acne.
A. Botanical Anti-Acne Ingredients
As explained above, topical skin compositions of the present invention can include Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, or Mushroom extract, or any combination thereof. These ingredients can be obtained from third party sellers. For instance, Arctium lappa (Burdock) root extract, extract obtained from the root of burdock, can be purchased from C&F Koei Phyto Corp. (USA) under the trades name BURDOCK ROOT EXTRACT™, ORGANIC BURDOCK EXTRACT BG-50™, from Indena SA (Spain) under the trade name PHYTELENE OF BURDOCK-ROOTS EN 422™, or from Greentech S.A. (France) under the trade names PHYTELENE COMPLEX EGX 232™, PHYTELENE COMPLEX EGX 247™, PHYTELENE COMPLEX EGX 252™, PHYTELENE OF BARDANE EG 195 LIQUID™, PHYTELENE OF BURDOCK EG 195 LIQUID™.
Epilobium angustifolium (Canadian Willowherb) extract obtained from the flower, leaf, and stem can be purchased from Atrium Innovations (France) under the trade names CANADIAN WILLOWHERB EXTRACT™ (5% clear), CANADIAN WILLOWHERB EXTRACT™ (5% in water), CANADIAN WILLOWHERB EXTRACT-10%™ (in glycerin), from Fytokem (Canada) under the trade names CANADIAN WILLOWHERB EXTRACT™ (5% clear), CANADIAN WILLOWHERB EXTRACT™ (5% in water), CANADIAN WILLOWHERB EXTRACT-10%™ (in glycerin), or from Greentech S.A. (France) under the trade names ARP 100 HUILEUX™, and SEBORILYS™. Epilobium angustifolium (Canadian Willowherb) extract obtained from the leaf can be purchased from Cosmetochem International (Germany) under the trade name HERBASEC ROSE BAY WILLOW-HERB™.
Pinus sylvestris bark extract, extract of the bark of Pinus sylvestris, can be purchased from Greentech S.A. (France) under the trade name EPICA™.
Ribes nigrum (Black Currant) leaf extract, extract from the leaf of Black Currant, can be purchased from Greentech S.A. (France) under the trade name EPICA™, from Alban Muller International (France) under the trade names BLACKCURRANT LEAF HPG TITRATED™, BLACKCURRANT LEAF HS™, and PHYTAMI of ORGANIC BLACKCURRANT™, and from Solabia Group (France) under the trade names AE COMPLEX BG™ and AE COMPLEX GLYCERIN™.
Peumus boldus (Boldo) leaf extract, extract from the leaves of Boldo, can be purchased from Bio-Botanica (USA) under the trade name BOLDO POWDERED EXTRACT™, from Phytocos (France) under the trade names AROME BOLDO™, EXTRAIT DE BOLDO LP1™, and EXTRAIT DE BOLDO SGLP™, or from Silab (France) under the trade names SCULPTURINE™ and SLIMACTIVE™.
Spiraea ulmaria (Meadow Sweet) extract obtained from the leaf can be purchased from Gattefosse (Canada) under the trade name CYTOBIO ULMAIRE™. Spiraea ulmaria extract obtained from the whole plant can be purchased from Active Concepts (USA) under the trade name ACB MEADOWSWEET EXTRACT™, ACB MEADOWSWEET EXTRACT 20%(™), from Silab (France) under the trade names DERMAPUR™, SEBONORMINE™, and SEBOREGUL™, or from Phytocos (France) under the trade names COMPLEXE AMINCISSANT LP1™, COMPLEXE AMINCISSANT SGLP™, EXTRAIT d'ULMAIRE LP1™, and EXTRAIT d'ULMAIRE SGLP™. Spiraea ulmaria extract obtained from the flower can be purchased from Indena S.A. (France) under the trade name SWEET SUPEXTRAT™ or from Greentech S.A. (France) under the trade names PHYTELENE COMPLEX EGX 250™, PHYTELENE OF QUEEN MEADOW EG 213 LIQUID™, and PHYTELENE OF ULMAIRE EG 213 LIQUID™, and SLIMMING™. Spiraea ulmaria extract obtained from the root can purchased from Active Organics (USA) under the trade names ACTIPHYTE OF MEADOWSWEET PG50™, CO ACTIPHYTE OF MEADOWSWEET AJ™, CO ACTIPHYTE OF MEADOWSWEET AL™, CO ACTIPHYTE OF MEADOWSWEET GL™, CO ACTIPHYTE OF MEADOWSWEET LIPO O™, CO ACTIPHYTE OF MEADOWSWEET LIPO RS™, CO ACTIPHYTE OF MEADOWSWEET LIPO S™, and CO ACTIPHYTE OF MEADOWSWEET LIPO SUN™.
Cystoseira amentacea/Caespitosa Brachycarpa extract, a water fraction prepared from Cystoseira amentacea Bory, Cystoseira caespitosa Sauvageau, and Cystoseira brachycarpa var. balearica (Sauvageau) Giaccone, can be purchased from Gelyma (France) or Biosil Technologies (USA) under the trade name SEA HEATHER™.
Hydrolyzed soy protein, which is hydrolysate of soy protein derived by acid, enzyme, or other methods of hydrolysis, can be purchased from MGP Ingredients Inc. (USA) under the trade name AQUA PRO™ SP, AQUA PRO™ SP 15, AQUA PRO™ SP 20, and AQUA PRO™ SPSF, or from Arch Personal Care Products (USA) under the trade names SOLU-SOY™ 25, SOLU-SOY™ EN-25, SOLU-SOY™ ENSD, or SOLU-SOY™ 25, or from Croda, Inc. (USA) under the trade names HYDROSOY 2000™ or HYDROSOY 2000 SF POWDER™, or from Active Concepts (USA) under the trade names AC SOY HYDROLYSATE™ or AC SOY HYDROLYSATE 30™.
Navy bean extract (also referred to as white bean extract), extract obtained from the navy bean—a small white kidney bean—can be purchased from InfraReady Products, Ltd. (Canada), under the trade name PRE-COOKED NAVY BEAN POWDER™.
Mushroom extract, extract obtained from mushrooms, can be purchased from Active Concepts (USA), under the trade names ACB MUSHROOM EXTRACT (POWDER) SM™, ACB MUSHROOM EXTRACT SM™, ACB SONGYI MUSHROOM EXTRACT™, ACB SONGYI MUSHROOM EXTRACT POWDER™, ABS MUSHROOM EXTRACT BG, or ABS MUSHROOM EXTRACT POWDER™.
Additional information and suppliers of the above-listed ingredients (and the corresponding trade names) can be found in International Cosmetic Ingredient Dictionary Handbook, 12th Edition (2008), which is incorporated by reference. Further, the extracts identified above can be produced by obtaining the corresponding fruit, seed, leaf, etc. to produce the extract by extraction methods which are known to those of ordinary skill in the art. The inventors also contemplate that other portions of the substrate (e.g., Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, or Mushroom extract) producing the extract can be used in the compositions and methods of the present invention. Non-limiting examples of the other portions include the whole fruit, whole vegetable, whole plant, whole tree, whole bush, seed, peel, fruit, stem, bark, leaf, root, flower, petal, bulb, etc. These other portions are described in the International Cosmetic Ingredient Dictionary Handbook, 12th Edition (2008), which is incorporated by reference.
B. Additional Anti-Acne Ingredients
Additional anti-acne ingredients can also be incorporated in the compositions of the present invention. Non-limiting examples of such additional ingredients include salicylic acid, benzoic acid, benzoyl peroxide, and tretinoin. These forms of anti-acne ingredient when used in effective amounts tend to produce dry, flaky, scaly skin and can also irritate the skin. These adverse symptoms can be reduced or prevented when the ingredients are incorporated into the compositions of the present invention. The symptoms can be reduced or prevented in instances where an effective amount (or excess of an effective amount) of such ingredients are used. This is an added benefit of the compositions of the present invention in that the efficacy of the compositions can be increased by use of such skin-caustic ingredients (e.g., salicylic acid, benzoic acid, benzoyl peroxide, and tretinoin) while preventing or reducing the unwanted side-effects produced by the caustic ingredients.
C. Oxygen Radical Absorbance Capacity
Oxygen Radical Absorption (or Absorbance) Capacity (ORAC) is an assay that measures the antioxidant activity of an ingredient or composition. In essence, it can quantify the degree and length of time it takes to inhibit the action of an oxidizing agent such as oxygen radicals that are known to cause damage cells (e.g., skin cells). The ORAC value of the compositions of the present invention can be determined by methods known to those of ordinary skill in the art (see U.S. Publication Nos. 2004/0109905 and 2005/0163880; Cao et al. (1993)), all of which are incorporated by reference). In summary, the assay described in Cao et al. (1993) measures the ability of antioxidant compounds in test materials to inhibit the decline of B-phycoerythrm (B-PE) fluorescence that is induced by a peroxyl radical generator, AAPH.
D. Compositions of the Present Invention
It is contemplated that the compositions of the present invention can include Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, Mushroom extract, an anti-acne ingredient (e.g., salicylic acid, benzoic acid, benzoyl peroxide, tretinoin, etc.), or an additional ingredient, or any combination thereof. Additionally, the compositions can include any number of combinations of additional ingredients described throughout this specification. The concentrations of the any ingredient within the compositions can vary. In non-limiting embodiments, for example, the compositions can comprise, consisting essentially of, or consist of, in their final form, for example, at least about 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.0010%, 0.0011%, 0.0012%, 0.0013%, 0.0014%, 0.0015%, 0.0016%, 0.0017%, 0.0018%, 0.0019%, 0.0020%, 0.0021%, 0.0022%, 0.0023%, 0.0024%, 0.0025%, 0.0026%, 0.0027%, 0.0028%, 0.0029%, 0.0030%, 0.0031%, 0.0032%, 0.0033%, 0.0034%, 0.0035%, 0.0036%, 0.0037%, 0.0038%, 0.0039%, 0.0040%, 0.0041%, 0.0042%, 0.0043%, 0.0044%, 0.0045%, 0.0046%, 0.0047%, 0.0048%, 0.0049%, 0.0050%, 0.0051%, 0.0052%, 0.0053%, 0.0054%, 0.0055%, 0.0056%, 0.0057%, 0.0058%, 0.0059%, 0.0060%, 0.0061%, 0.0062%, 0.0063%, 0.0064%, 0.0065%, 0.0066%, 0.0067%, 0.0068%, 0.0069%, 0.0070%, 0.0071%, 0.0072%, 0.0073%, 0.0074%, 0.0075%, 0.0076%, 0.0077%, 0.0078%, 0.0079%, 0.0080%, 0.0081%, 0.0082%, 0.0083%, 0.0084%, 0.0085%, 0.0086%, 0.0087%, 0.0088%, 0.0089%, 0.0090%, 0.0091%, 0.0092%, 0.0093%, 0.0094%, 0.0095%, 0.0096%, 0.0097%, 0.0098%, 0.0099%, 0.0100%, 0.0200%, 0.0250%, 0.0275%, 0.0300%, 0.0325%, 0.0350%, 0.0375%, 0.0400%, 0.0425%, 0.0450%, 0.0475%, 0.0500%, 0.0525%, 0.0550%, 0.0575%, 0.0600%, 0.0625%, 0.0650%, 0.0675%, 0.0700%, 0.0725%, 0.0750%, 0.0775%, 0.0800%, 0.0825%, 0.0850%, 0.0875%, 0.0900%, 0.0925%, 0.0950%, 0.0975%, 0.1000%, 0.1250%, 0.1500%, 0.1750%, 0.2000%, 0.2250%, 0.2500%, 0.2750%, 0.3000%, 0.3250%, 0.3500%, 0.3750%, 0.4000%, 0.4250%, 0.4500%, 0.4750%, 0.5000%, 0.5250%, 0.0550%, 0.5750%, 0.6000%, 0.6250%, 0.6500%, 0.6750%, 0.7000%, 0.7250%, 0.7500%, 0.7750%, 0.8000%, 0.8250%, 0.8500%, 0.8750%, 0.9000%, 0.9250%, 0.9500%, 0.9750%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%, 5.1%, 5.2%, 5.3%, 5.4%, 5.5%, 5.6%, 5.7%, 5.8%, 5.9%, 6.0%, 6.1%, 6.2%, 6.3%, 6.4%, 6.5%, 6.6%, 6.7%, 6.8%, 6.9%, 7.0%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%, 7.7%, 7.8%, 7.9%, 8.0%, 8.1%, 8.2%, 8.3%, 8.4%, 8.5%, 8.6%, 8.7%, 8.8%, 8.9%, 9.0%, 9.1%, 9.2%, 9.3%, 9.4%, 9.5%, 9.6%, 9.7%, 9.8%, 9.9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 35%, 40%, 45%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% or any range derivable therein, of at least one of the ingredients that are mentioned throughout the specification and claims. In non-limiting aspects, the percentage can be calculated by weight or volume of the total composition. A person of ordinary skill in the art would understand that the concentrations can vary depending on the addition, substitution, and/or subtraction of ingredients in a given composition.
The disclosed compositions of the present invention may also include various antioxidants to retard oxidation of one or more components. Additionally, the prevention of the action of microorganisms can be brought about by preservatives such as various antibacterial and antifungal agents, including but not limited to parabens (e.g., methylparabens, propylparabens), chlorobutanol, phenol, sorbic acid, thimerosal or combinations thereof.
E. Vehicles
The compositions of the present invention can be incorporated into all types of vehicles. Non-limiting examples of suitable vehicles include emulsions (e.g., water-in-oil, water-in-oil-in-water, oil-in-water, silicone-in-water, water-in-silicone, oil-in-water-in-oil, oil-in-water-in-silicone emulsions), creams, lotions, solutions (both aqueous and hydro-alcoholic), anhydrous bases (such as lipsticks and powders), gels, and ointments or by other method or any combination of the forgoing as would be known to one of ordinary skill in the art (Remington's, 1990). Variations and other appropriate vehicles will be apparent to the skilled artisan and are appropriate for use in the present invention. In certain aspects, it is important that the concentrations and combinations of the compounds, ingredients, and agents be selected in such a way that the combinations are chemically compatible and do not form complexes which precipitate from the finished product.
It is also contemplated that ingredients identified throughout this specification, including but not limited to Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, Mushroom extract, or any combination thereof, or an additional anti-acne ingredient (e.g., salicylic acid, benzoic acid, benzoyl peroxide, tretinoin, etc.), or any combination thereof, can be individually or combinatorially encapsulated for delivery to a target area such as skin. Non-limiting examples of encapsulation techniques include the use of liposomes, vesicles, and/or nanoparticles (e.g., biodegradable and non-biodegradable colloidal particles comprising polymeric materials in which the ingredient is trapped, encapsulated, and/or absorbed—examples include nanospheres and nanocapsules) that can be used as delivery vehicles to deliver the ingredient to skin (see, e.g., U.S. Pat. No. 6,387,398; U.S. Pat. No. 6,203,802; U.S. Pat. No. 5,411,744; Kreuter 1998).
F. Cosmetic Products and Articles of Manufacture
The composition of the present invention can also be used in many cosmetic products including, but not limited to, sunscreen products, sunless skin tanning products, hair products, finger nail products, moisturizing creams, skin benefit creams and lotions, softeners, day lotions, gels, ointments, foundations, night creams, lipsticks, cleansers, toners, masks, or other known cosmetic products or applications. Additionally, the cosmetic products can be formulated as leave-on or rinse-off products. In certain aspects, the compositions of the present invention are stand-alone products.
G. Additional Ingredients
In addition to the Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, Mushroom extract, and/or an additional anti-acne ingredient (e.g., salicylic acid, benzoic acid, benzoyl peroxide, tretinoin, etc.) disclosed throughout this specification, compositions of the present invention can include additional ingredients such as cosmetic ingredients and pharmaceutical active ingredients. Non-limiting examples of these additional ingredients are described in the following subsections.
1. Cosmetic Ingredients
The CTFA International Cosmetic Ingredient Dictionary and Handbook (2004 and 2008) describes a wide variety of non-limiting cosmetic ingredients that can be used in the context of the present invention. Examples of these ingredient classes include: fragrances (artificial and natural), dyes and color ingredients (e.g., Blue 1, Blue 1 Lake, Red 40, titanium dioxide, D&C blue no. 4, D&C green no. 5, D&C orange no. 4, D&C red no. 17, D&C red no. 33, D&C violet no. 2, D&C yellow no. 10, and D&C yellow no. 11), adsorbents, lubricants, solvents, moisturizers (including, e.g., emollients, humectants, film formers, occlusive agents, and agents that affect the natural moisturization mechanisms of the skin), water-repellants, UV absorbers (physical and chemical absorbers such as paraminobenzoic acid (“PABA”) and corresponding PABA derivatives, titanium dioxide, zinc oxide, etc.), essential oils, vitamins (e.g. A, B, C, D, E, and K), trace metals (e.g. zinc, calcium and selenium), anti-irritants (e.g. steroids and non-steroidal anti-inflammatories), botanical extracts (e.g. aloe vera, chamomile, cucumber extract, ginkgo biloba, ginseng, and rosemary), anti-microbial agents, antioxidants (e.g., BHT and tocopherol), chelating agents (e.g., disodium EDTA and tetrasodium EDTA), preservatives (e.g., methylparaben and propylparaben), pH adjusters (e.g., sodium hydroxide and citric acid), absorbents (e.g., aluminum starch octenylsuccinate, kaolin, corn starch, oat starch, cyclodextrin, talc, and zeolite), skin bleaching and lightening agents (e.g., hydroquinone and niacinamide lactate), humectants (e.g., sorbitol, urea, and manitol), exfoliants, waterproofing agents (e.g., magnesium/aluminum hydroxide stearate), skin conditioning agents (e.g., aloe extracts, allantoin, bisabolol, ceramides, dimethicone, hyaluronic acid, and dipotassium glycyrrhizate). Non-limiting examples of some of these ingredients are provided in the following subsections.
a. UV Absorption Agents
UV absorption agents that can be used in combination with the compositions of the present invention include chemical and physical sunblocks. Non-limiting examples of chemical sunblocks that can be used include para-aminobenzoic acid (PABA), PABA esters (glyceryl PABA, amyldimethyl PABA and octyldimethyl PABA), butyl PABA, ethyl PABA, ethyl dihydroxypropyl PABA, benzophenones (oxybenzone, sulisobenzone, benzophenone, and benzophenone-1 through 12), cinnamates (octyl methoxycinnamate, isoamyl p-methoxycinnamate, octylmethoxy cinnamate, cinoxate, diisopropyl methyl cinnamate, DEA-methoxycinnamate, ethyl diisopropylcinnamate, glyceryl octanoate dimethoxycinnamate and ethyl methoxycinnamate), cinnamate esters, salicylates (homomethyl salicylate, benzyl salicylate, glycol salicylate, isopropylbenzyl salicylate, etc.), anthranilates, ethyl urocanate, homosalate, octisalate, dibenzoylmethane derivatives (e.g., avobenzone), octocrylene, octyl triazone, digalloy trioleate, glyceryl aminobenzoate, lawsone with dihydroxyacetone, ethylhexyl triazone, dioctyl butamido triazone, benzylidene malonate polysiloxane, terephthalylidene dicamphor sulfonic acid, disodium phenyl dibenzimidazole tetrasulfonate, diethylamino hydroxybenzoyl hexyl benzoate, bis diethylamino hydroxybenzoyl benzoate, bis benzoxazoylphenyl ethylhexylimino triazine, drometrizole trisiloxane, methylene bis-benzotriazolyl tetramethylbutylphenol, and bis-ethylhexyloxyphenol methoxyphenyltriazine, 4-methylbenzylidenecamphor, and isopentyl 4-methoxycinnamate. Non-limiting examples of physical sunblocks include, kaolin, talc, petrolatum and metal oxides (e.g., titanium dioxide and zinc oxide).
b. Moisturizing Agents
Non-limiting examples of moisturizing agents that can be used with the compositions of the present invention include amino acids, chondroitin sulfate, diglycerin, erythritol, fructose, glucose, glycerin, glycerol polymers, glycol, 1,2,6-hexanetriol, honey, hyaluronic acid, hydrogenated honey, hydrogenated starch hydrolysate, inositol, lactitol, maltitol, maltose, mannitol, natural moisturizing factor, PEG-15 butanediol, polyglyceryl sorbitol, salts of pyrollidone carboxylic acid, potassium PCA, propylene glycol, sodium glucuronate, sodium PCA, sorbitol, sucrose, trehalose, urea, and xylitol.
Other examples include acetylated lanolin, acetylated lanolin alcohol, alanine, algae extract, aloe barbadensis, aloe-barbadensis extract, aloe barbadensis gel, althea officinalis extract, apricot (prunus armeniaca) kernel oil, arginine, arginine aspartate, arnica montana extract, aspartic acid, avocado (persea gratissima) oil, barrier sphingolipids, butyl alcohol, beeswax, behenyl alcohol, beta-sitosterol, birch (betula alba) bark extract, borage (borago officinalis) extract, butcherbroom (ruscus aculeatus) extract, butylene glycol, calendula officinalis extract, calendula officinalis oil, candelilla (euphorbia cerifera) wax, canola oil, caprylic/capric triglyceride, cardamon (elettaria cardamomum) oil, carnauba (copernicia cerifera) wax, carrot (daucus carota sativa) oil, castor (ricinus communis) oil, ceramides, ceresin, ceteareth-5, ceteareth-12, ceteareth-20, cetearyl octanoate, ceteth-20, ceteth-24, cetyl acetate, cetyl octanoate, cetyl palmitate, chamomile (anthemis nobilis) oil, cholesterol, cholesterol esters, cholesteryl hydroxystearate, citric acid, clary (salvia sclarea) oil, cocoa (theobroma cacao) butter, coco-caprylate/caprate, coconut (cocos nucifera) oil, collagen, collagen amino acids, corn (zea mays) oil, fatty acids, decyl oleate, dimethicone copolyol, dimethiconol, dioctyl adipate, dioctyl succinate, dipentaerythrityl hexacaprylate/hexacaprate, DNA, erythritol, ethoxydiglycol, ethyl linoleate, eucalyptus globulus oil, evening primrose (oenothera biennis) oil, fatty acids, geranium maculatum oil, glucosamine, glucose glutamate, glutamic acid, glycereth-26, glycerin, glycerol, glyceryl distearate, glyceryl hydroxystearate, glyceryl laurate, glyceryl linoleate, glyceryl myristate, glyceryl oleate, glyceryl stearate, glyceryl stearate SE, glycine, glycol stearate, glycol stearate SE, glycosaminoglycans, grape (vitis vinifera) seed oil, hazel (corylus americana) nut oil, hazel (corylus avellana) nut oil, hexylene glycol, hyaluronic acid, hybrid safflower (carthamus tinctorius) oil, hydrogenated castor oil, hydrogenated coco-glycerides, hydrogenated coconut oil, hydrogenated lanolin, hydrogenated lecithin, hydrogenated palm glyceride, hydrogenated palm kernel oil, hydrogenated soybean oil, hydrogenated tallow glyceride, hydrogenated vegetable oil, hydrolyzed collagen, hydrolyzed elastin, hydrolyzed glycosaminoglycans, hydrolyzed keratin, hydrolyzed soy protein, hydroxylated lanolin, hydroxyproline, isocetyl stearate, isocetyl stearoyl stearate, isodecyl oleate, isopropyl isostearate, isopropyl lanolate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, isostearamide DEA, isostearic acid, isostearyl lactate, isostearyl neopentanoate, jasmine (jasminum officinale) oil, jojoba (buxus chinensis) oil, kelp, kukui (aleurites moluccana) nut oil, lactamide MEA, laneth-16, laneth-10 acetate, lanolin, lanolin acid, lanolin alcohol, lanolin oil, lanolin wax, lavender (lavandula angustifolia) oil, lecithin, lemon (citrus medica limonum) oil, linoleic acid, linolenic acid, macadamia ternifolia nut oil, maltitol, matricaria (chamomilla recutita) oil, methyl glucose sesquistearate, methylsilanol PCA, mineral oil, mink oil, mortierella oil, myristyl lactate, myristyl myristate, myristyl propionate, neopentyl glycol dicaprylate/dicaprate, octyldodecanol, octyldodecyl myristate, octyldodecyl stearoyl stearate, octyl hydroxystearate, octyl palmitate, octyl salicylate, octyl stearate, oleic acid, olive (olea europaea) oil, orange (citrus aurantium dulcis) oil, palm (elaeis guineensis) oil, palmitic acid, pantethine, panthenol, panthenyl ethyl ether, paraffin, PCA, peach (prunus persica) kernel oil, peanut (arachis hypogaea) oil, PEG-8 C12-18 ester, PEG-15 cocamine, PEG-150 distearate, PEG-60 glyceryl isostearate, PEG-5 glyceryl stearate, PEG-30 glyceryl stearate, PEG-7 hydrogenated castor oil, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-20 methyl glucose sesquistearate, PEG40 sorbitan peroleate, PEG-5 soy sterol, PEG-10 soy sterol, PEG-2 stearate, PEG-8 stearate, PEG-20 stearate, PEG-32 stearate, PEG40 stearate, PEG-50 stearate, PEG-100 stearate, PEG-150 stearate, pentadecalactone, peppermint (mentha piperita) oil, petrolatum, phospholipids, polyamino sugar condensate, polyglyceryl-3 diisostearate, polyquaternium-24, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polysorbate 85, potassium myristate, potassium palmitate, propylene glycol, propylene glycol dicaprylate/dicaprate, propylene glycol dioctanoate, propylene glycol dipelargonate, propylene glycol laurate, propylene glycol stearate, propylene glycol stearate SE, PVP, pyridoxine dipalmitate, retinol, retinyl palmitate, rice (oryza sativa) bran oil, RNA, rosemary (rosmarinus officinalis) oil, rose oil, safflower (carthamus tinctorius) oil, sage (salvia officinalis) oil, sandalwood (santalum album) oil, serine, serum protein, sesame (sesamum indicum) oil, shea butter (butyrospermum parkii), silk powder, sodium chondroitin sulfate, sodium hyaluronate, sodium lactate, sodium palmitate, sodium PCA, sodium polyglutamate, soluble collagen, sorbitan laurate, sorbitan oleate, sorbitan palmitate, sorbitan sesquioleate, sorbitan stearate, sorbitol, soybean (glycine soja) oil, sphingolipids, squalane, squalene, stearamide MEA-stearate, stearic acid, stearoxy dimethicone, stearoxytrimethylsilane, stearyl alcohol, stearyl glycyrrhetinate, stearyl heptanoate, stearyl stearate, sunflower (helianthus annuus) seed oil, sweet almond (prunus amygdalus dulcis) oil, synthetic beeswax, tocopherol, tocopheryl acetate, tocopheryl linoleate, tribehenin, tridecyl neopentanoate, tridecyl stearate, triethanolamine, tristearin, urea, vegetable oil, water, waxes, wheat (triticum vulgare) germ oil, and ylang ylang (cananga odorata) oil.
c. Antioxidants
Non-limiting examples of antioxidants that can be used with the compositions of the present invention include acetyl cysteine, ascorbic acid polypeptide, ascorbyl dipalmitate, ascorbyl methylsilanol pectinate, ascorbyl palmitate, ascorbyl stearate, BHA, BHT, t-butyl hydroquinone, cysteine, cysteine HCl, diamylhydroquinone, di-t-butylhydroquinone, dicetyl thiodipropionate, dioleyl tocopheryl methylsilanol, disodium ascorbyl sulfate, distearyl thiodipropionate, ditridecyl thiodipropionate, dodecyl gallate, erythorbic acid, esters of ascorbic acid, ethyl ferulate, ferulic acid, gallic acid esters, hydroquinone, isooctyl thioglycolate, kojic acid, magnesium ascorbate, magnesium ascorbyl phosphate, methylsilanol ascorbate, natural botanical anti-oxidants such as green tea or grape seed extracts, nordihydroguaiaretic acid, octyl gallate, phenylthioglycolic acid, potassium ascorbyl tocopheryl phosphate, potassium sulfite, propyl gallate, quinones, rosmarinic acid, sodium ascorbate, sodium bisulfite, sodium erythorbate, sodium metabisulfite, sodium sulfite, superoxide dismutase, sodium thioglycolate, sorbityl furfural, thiodiglycol, thiodiglycolamide, thiodiglycolic acid, thioglycolic acid, thiolactic acid, thiosalicylic acid, tocophereth-5, tocophereth-10, tocophereth-12, tocophereth-18, tocophereth-50, tocopherol, tocophersolan, tocopheryl acetate, tocopheryl linoleate, tocopheryl nicotinate, tocopheryl succinate, and tris(nonylphenyl)phosphite.
d. Structuring Agents
In other non-limiting aspects, the compositions of the present invention can include a structuring agent. Structuring agent, in certain aspects, assist in providing rheological characteristics to the composition to contribute to the composition's stability. In other aspects, structuring agents can also function as an emulsifier or surfactant. Non-limiting examples of structuring agents include stearic acid, palmitic acid, stearyl alcohol, cetyl alcohol, behenyl alcohol, stearic acid, palmitic acid, the polyethylene glycol ether of stearyl alcohol having an average of about 1 to about 21 ethylene oxide units, the polyethylene glycol ether of cetyl alcohol having an average of about 1 to about 5 ethylene oxide units, and mixtures thereof.
e. Emulsifiers
In certain aspects of the present invention, the compositions do not include an emulsifier. In other aspects, however, the compositions can include one or more emulsifiers. Emulsifiers can reduce the interfacial tension between phases and improve the formulation and stability of an emulsion. The emulsifiers can be nonionic, cationic, anionic, and zwitterionic emulsifiers (See McCutcheon's (1986); U.S. Pat. Nos. 5,011,681; 4,421,769; 3,755,560). Non-limiting examples include esters of glycerin, esters of propylene glycol, fatty acid esters of polyethylene glycol, fatty acid esters of polypropylene glycol, esters of sorbitol, esters of sorbitan anhydrides, carboxylic acid copolymers, esters and ethers of glucose, ethoxylated ethers, ethoxylated alcohols, alkyl phosphates, polyoxyethylene fatty ether phosphates, fatty acid amides, acyl lactylates, soaps, TEA stearate, DEA oleth-3 phosphate, polyethylene glycol 20 sorbitan monolaurate (polysorbate 20), polyethylene glycol 5 soya sterol, steareth-2, steareth-20, steareth-21, ceteareth-20, PPG-2 methyl glucose ether distearate, ceteth-10, polysorbate 80, cetyl phosphate, potassium cetyl phosphate, diethanolamine cetyl phosphate, polysorbate 60, glyceryl stearate, PEG-100 stearate, and mixtures thereof.
f. Silicone Containing Compounds
In non-limiting aspects, silicone containing compounds include any member of a family of polymeric products whose molecular backbone is made up of alternating silicon and oxygen atoms with side groups attached to the silicon atoms. By varying the —Si—O— chain lengths, side groups, and crosslinking, silicones can be synthesized into a wide variety of materials. They can vary in consistency from liquid to gel to solids.
The silicone containing compounds that can be used in the context of the present invention include those described in this specification or those known to a person of ordinary skill in the art. Non-limiting examples include silicone oils (e.g., volatile and non-volatile oils), gels, and solids. In certain aspects, the silicon containing compounds includes a silicone oils such as a polyorganosiloxane. Non-limiting examples of polyorganosiloxanes include dimethicone, cyclomethicone, polysilicone-11, phenyl trimethicone, trimethylsilylamodimethicone, stearoxytrimethylsilane, or mixtures of these and other organosiloxane materials in any given ratio in order to achieve the desired consistency and application characteristics depending upon the intended application (e.g., to a particular area such as the skin, hair, or eyes). A “volatile silicone oil” includes a silicone oil have a low heat of vaporization, i.e. normally less than about 50 cal per gram of silicone oil. Non-limiting examples of volatile silicone oils include: cyclomethicones such as Dow Corning 344 Fluid, Dow Corning 345 Fluid, Dow Corning 244 Fluid, and Dow Corning 245 Fluid, Volatile Silicon 7207 (Union Carbide Corp., Danbury, Conn.); low viscosity dimethicones, i.e. dimethicones having a viscosity of about 50 cst or less (e.g., dimethicones such as Dow Corning 200-0.5 cst Fluid). The Dow Corning Fluids are available from Dow Corning Corporation, Midland, Mich. Cyclomethicone and dimethicone are described in the Third Edition of the CTFA Cosmetic Ingredient Dictionary (incorporated by reference) as cyclic dimethyl polysiloxane compounds and a mixture of fully methylated linear siloxane polymers end-blocked with trimethylsiloxy units, respectively. Other non-limiting volatile silicone oils that can be used in the context of the present invention include those available from General Electric Co., Silicone Products Div., Waterford, N.Y. and SWS Silicones Div. of Stauffer Chemical Co., Adrian, Mich.
g. Essential Oils
Essential oils include oils derived from herbs, flowers, trees, and other plants. Such oils are typically present as tiny droplets between the plant's cells, and can be extracted by several method known to those of skill in the art (e.g., steam distilled, enfleurage (i.e., extraction by using fat), maceration, solvent extraction, or mechanical pressing). When these types of oils are exposed to air they tend to evaporate (i.e., a volatile oil). As a result, many essential oils are colorless, but with age they can oxidize and become darker. Essential oils are insoluble in water and are soluble in alcohol, ether, fixed oils (vegetal), and other organic solvents. Typical physical characteristics found in essential oils include boiling points that vary from about 160° to 240° C. and densities ranging from about 0.759 to about 1.096.
Essential oils typically are named by the plant from which the oil is found. For example, rose oil or peppermint oil are derived from rose or peppermint plants, respectively. Non-limiting examples of essential oils that can be used in the context of the present invention include sesame oil, macadamia nut oil, tea tree oil, evening primrose oil, Spanish sage oil, Spanish rosemary oil, coriander oil, thyme oil, pimento berries oil, rose oil, anise oil, balsam oil, bergamot oil, rosewood oil, cedar oil, chamomile oil, sage oil, clary sage oil, clove oil, cypress oil, eucalyptus oil, fennel oil, sea fennel oil, frankincense oil, geranium oil, ginger oil, grapefruit oil, jasmine oil, juniper oil, lavender oil, lemon oil, lemongrass oil, lime oil, mandarin oil, marjoram oil, myrrh oil, neroli oil, orange oil, patchouli oil, pepper oil, black pepper oil, petitgrain oil, pine oil, rose otto oil, rosemary oil, sandalwood oil, spearmint oil, spikenard oil, vetiver oil, wintergreen oil, or ylang ylang. Other essential oils known to those of skill in the art are also contemplated as being useful within the context of the present invention.
h. Thickening Agents
Thickening agents, including thickener or gelling agents, include substances which that can increase the viscosity of a composition. Thickeners includes those that can increase the viscosity of a composition without substantially modifying the efficacy of the active ingredient within the composition. Thickeners can also increase the stability of the compositions of the present invention. In certain aspects of the present invention, thickeners include hydrogenated polyisobutene or trihydroxystearin, or a mixture of both.
Non-limiting examples of additional thickening agents that can be used in the context of the present invention include carboxylic acid polymers, crosslinked polyacrylate polymers, polyacrylamide polymers, polysaccharides, and gums. Examples of carboxylic acid polymers include crosslinked compounds containing one or more monomers derived from acrylic acid, substituted acrylic acids, and salts and esters of these acrylic acids and the substituted acrylic acids, wherein the crosslinking agent contains two or more carbon-carbon double bonds and is derived from a polyhydric alcohol (see U.S. Pat. Nos. 5,087,445; 4,509,949; 2,798,053; CTFA International Cosmetic Ingredient Dictionary, Fourth edition, 1991, pp. 12 and 80). Examples of commercially available carboxylic acid polymers include carbomers, which are homopolymers of acrylic acid crosslinked with allyl ethers of sucrose or pentaerytritol (e.g., Carbopol™ 900 series from B.F. Goodrich).
Non-limiting examples of crosslinked polyacrylate polymers include cationic and nonionic polymers. Examples are described in U.S. Pat. Nos. 5,100,660; 4,849,484; 4,835,206; 4,628,078; 4,599,379).
Non-limiting examples of polyacrylamide polymers (including nonionic polyacrylamide polymers including substituted branched or unbranched polymers) include polyacrylamide, isoparaffin and laureth-7, multi-block copolymers of acrylamides and substituted acrylamides with acrylic acids and substituted acrylic acids.
Non-limiting examples of polysaccharides include cellulose, carboxymethyl hydroxyethylcellulose, cellulose acetate propionate carboxylate, hydroxyethylcellulose, hydroxyethyl ethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, methyl hydroxyethylcellulose, microcrystalline cellulose, sodium cellulose sulfate, and mixtures thereof. Another example is an alkyl substituted cellulose where the hydroxy groups of the cellulose polymer is hydroxyalkylated (preferably hydroxy ethylated or hydroxypropylated) to form a hydroxyalkylated cellulose which is then further modified with a C10-C30 straight chain or branched chain alkyl group through an ether linkage. Typically these polymers are ethers of C10-C30 straight or branched chain alcohols with hydroxyalkylcelluloses. Other useful polysaccharides include scleroglucans comprising a linear chain of (1-3) linked glucose units with a (1-6) linked glucose every three unit.
Non-limiting examples of gums that can be used with the present invention include acacia, agar, algin, alginic acid, ammonium alginate, amylopectin, calcium alginate, calcium carrageenan, carnitine, carrageenan, dextrin, gelatin, gellan gum, guar gum, guar hydroxypropyltrimonium chloride, hectorite, hyaluroinic acid, hydrated silica, hydroxypropyl chitosan, hydroxypropyl guar, karaya gum, kelp, locust bean gum, natto gum, potassium alginate, potassium carrageenan, propylene glycol alginate, sclerotium gum, sodium carboyxmethyl dextran, sodium carrageenan, tragacanth gum, xanthan gum, and mixtures thereof.
i. Preservatives
Non-limiting examples of preservatives that can be used in the context of the present invention include quaternary ammonium preservatives such as polyquaternium-1 and benzalkonium halides (e.g., benzalkonium chloride (“BAC”) and benzalkonium bromide), parabens (e.g., methylparabens and propylparabens), phenoxyethanol, benzyl alcohol, chlorobutanol, phenol, sorbic acid, thimerosal or combinations thereof.
2. Pharmaceutical Ingredients
Pharmaceutical active agents are also contemplated as being useful with the compositions of the present invention. Non-limiting examples of pharmaceutical active agents include agents used to treat rosacea, analgesics, anesthetics, anorectals, antihistamines, anti-inflammatory agents including non-steroidal anti-inflammatory drugs, antibiotics, antifungals, antivirals, antimicrobials, anti-cancer actives, scabicides, pediculicides, antineoplastics, antiperspirants, antipruritics, antipsoriatic agents, antiseborrheic agents, biologically active proteins and peptides, burn treatment agents, cauterizing agents, depigmenting agents, depilatories, diaper rash treatment agents, enzymes, hair growth stimulants, hair growth retardants including DFMO and its salts and analogs, hemostatics, kerotolytics, canker sore treatment agents, cold sore treatment agents, dental and periodontal treatment agents, photosensitizing actives, skin protectant/barrier agents, steroids including hormones and corticosteroids, sunburn treatment agents, sunscreens, transdermal actives, nasal actives, vaginal actives, wart treatment agents, wound treatment agents, wound healing agents, etc.
H. Kits
Kits are also contemplated as being used in certain aspects of the present invention. For instance, compositions of the present invention can be included in a kit. A kit can include a container. Containers can include a bottle, a metal tube, a laminate tube, a plastic tube, a dispenser, a pressurized container, a barrier container, a package, a compartment, a lipstick container, a compact container, cosmetic pans that can hold cosmetic compositions, or other types of containers such as injection or blow-molded plastic containers into which the dispersions or compositions or desired bottles, dispensers, or packages are retained. The kit and/or container can include indicia on its surface. The indicia, for example, can be a word, a phrase, an abbreviation, a picture, or a symbol.
The containers can dispense a pre-determined amount of the composition. In other embodiments, the container can be squeezed (e.g., metal, laminate, or plastic tube) to dispense a desired amount of the composition. The composition can be dispensed as a spray, an aerosol, a liquid, a fluid, or a semi-solid. The containers can have spray, pump, or squeeze mechanisms. A kit can also include instructions for employing the kit components as well the use of any other compositions included in the container. Instructions can include an explanation of how to apply, use, and maintain the compositions.
EXAMPLES
The following examples are included to demonstrate certain non-limiting aspects of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.
Example 1 Testing Vehicles
Non-limiting examples of compositions of the present invention are described in Tables 1 and 2. These compositions can be used as vehicles to test the efficacy of the active ingredients to treat skin.
TABLE 1*
Ingredient % Concentration (by weight)
Phase A
Water q.s. to 100%
Xanthum gum 0.1
M-paraben 0.15
P-paraben 0.1
Citric acid 0.01
Phase B
Cetyl alcohol 4.0
Glyceryl stearate + PEG 100 4.0
Octyl palmitate 4.0
Dimethicone 1.0
Tocopheryl acetate 0.2
Phase C
Active Ingredients** 2.0
*Sprinkle Xanthum gum in water and mix for 10 min. Subsequently, add all ingredients in phase A and heat to 70-75° C.. Add all items in phase B to separate beaker and heat to 70-75° C.. Mix phases A and B at 70-75° C.. Continue mixing and allow composition to cool to 30° C.. Subsequently, add phase C ingredient while mixing.
**Any of the active ingredients (or combination thereof) described in the specification can be used. For instance, the active ingredients can include Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, Mushroom extract, or an anti-acne ingredient (e.g., salicylic acid, benzylic acid, benzoyl peroxide, tretinoin, etc.) or any combination thereof. Although the total amount of active ingredients in the Table 1 formulation is 2% w/w, it is contemplated that the amount of active ingredients can be increased or decreased to achieve a desired result, where the water amount can be increased/decreased accordingly (e.g., q.s.).
TABLE 2*
Ingredient % Concentration (by weight)
Phase A
Water q.s. to 100%
M-paraben 0.2
P-paraben 0.1
Na2 EDTA 0.1
Shea butter 4.5
Petrolatum 4.5
Glycerin 4.0
Propylene Glycol 2.0
Finsolve TN 2.0
Phase B
Sepigel 305 2.0
Phase C
Active Ingredient(s)** 2.0
*Add ingredients in phase A to beaker and heat to 70-75° C. while mixing. Subsequently, add the phase B ingredient with phase A and cool to 30° C. with mixing. Subsequently, add phase C ingredient while mixing.
**Any of the active ingredients (or combination thereof) described in the specification can be used. For instance, the active ingredients can include Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, Hydrolyzed soy protein, Navy bean extract, Mushroom extract, or an anti-acne ingredient (e.g., salicylic acid, benzylic acid, benzoyl peroxide, tretinoin, etc.) or any combination thereof. Although the total amount of active ingredients in the Table 1 formulation is 2% w/w, it is contemplated that the amount of active ingredients can be increased or decreased to achieve a desired result, where the water amount can be increased/decreased accordingly (e.g., q.s.).
Example 2 Non-Limiting Product Formulations
Non-limiting skin product formulations of the present invention is described in Tables 3-9. The compositions can be made by any known methods in the art. For instance, simple mixing of the ingredients into a container can be used. Further, it is contemplated that additional ingredients can be added to the product formulations, listed ingredients can be replaced, and/or listed ingredients can be removed. The concentration ranges of the ingredients can be modified.
TABLE 3
(Cleanser)
Ingredient % Concentration (by weight)
Water q.s. to 100%
Sodium C14-16 Olefin Sulfonate 17.0
Cocamidopropyl Betaine 6.0
Sodium Chloride 2.0
Salicylic Acid 0.5
Disodium EDTA 0.3
Phenoxyethanol 0.1
Butylene Glycol 0.1
Propylene Glycol 0.1
Citric Acid 0.1
Botanical Extracts* 0.01
*Mixture of Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, and Cystoseira amentacea/Caespitosa Brachycarpa extract.
TABLE 4
(Lotion)
Ingredient % Concentration (by weight)
Water q.s. to 100%
Butylene Glycol 3.0
Dimethicone 3.0
Glycerin 2.0
Ammonium Acryloyldimethyltaurate/VP 1.0
Polysorbate 20 1.0
Propylene Glycol 1.0
Salicylic Acid 0.5
Triethanolamine 0.5
Butyl Avocadate 0.5
Phenoxyethanol 0.1
Citric Acid 0.05
Botanical Extracts* 0.1
*Mixture of Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, and Cystoseira amentacea/Caespitosa Brachycarpa extract.
TABLE 5
(Cream)
Ingredient % Concentration (by weight)
Water q.s. to 100%
Ethylhexyl Palmitate 10.0
Stearyl Alcohol 4.0
Glycerin 3.0
Propylene Glycol 1.0
Polysorbate 60 1.0
Salicylic Acid 0.5
Triethanolamine 0.5
Butyl Avocadate 0.5
Citric Acid 0.1
Butylene Glycol 0.01
Botanical Extracts* 0.1
*Mixture of Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, and Cystoseira amentacea/Caespitosa Brachycarpa extract.
TABLE 6
(Body Spray)
Ingredient % Concentration (by weight)
Water q.s. to 100%
Denatured Alcohol 35.0
Butylene Glycol 5.0
Salicylic Acid 2.0
Panthenol 0.3
Butylene Glycol 0.01
Citric Acid 0.1
Botanical Extracts* 0.1
*Mixture of Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, and Cystoseira amentacea/Caespitosa Brachycarpa extract.
TABLE 7
(Cream)
Ingredient % Concentration (by weight)
Water q.s. to 100%
Ethylhexyl Palmitate 10.0
Stearyl Alcohol 4.0
Glycerin 3.0
Triethanolamine 2.0
Salicylic Acid 2.0
Polysorbate 60 1.0
Propylene Glycol 1.0
Glyceryl Stearate 0.5
Dimethicone/Vinyl Dimethicone 0.5
Crosspolymer
Retinly Palmitate 0.5
Steareth-20 0.5
Butyl Avocadate 0.5
Ethylene/Acrylic Acid Copolymer 0.5
Butylene Glycol 0.01
Citric Acid 0.1
Botanical Extracts** 0.1
*Mixture of Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, and Cystoseira amentacea/Caespitosa Brachycarpa extract.
TABLE 8
(Serum)
Ingredient % Concentration (by weight)
Water q.s. to 100%
Butylene Glycol 4.0
Dimethicone 3.0
Salicylic Acid 2.0
Triethanolamine 2.0
Glycerin 2.0
Ammonium 2.0
Acryloyldimethyltaurate/VP Copol.
Propylene Glycol 1.0
Polysorbate 20 1.0
Butyl Avocadate 0.5
Citric Acid 0.1
Botanical Extracts** 0.1
*Mixture of Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, and Cystoseira amentacea/Caespitosa Brachycarpa extract.
TABLE 9
(Cleanser)
Ingredient % Concentration (by weight)
Water q.s. to 100%
Sodium C14-16 Olefin Sulfonate 17.0
Cocamidopropyl Betain 6.0
Salicylic Acid 2.0
Sodium Chloride 1.0
Triethanolamine 0.5
Butylene Glycol 0.1
Propylene Glycol 0.1
Citric Acid 0.1
Botanical Extracts** 0.01
*Mixture of Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, and Cystoseira amentacea/Caespitosa Brachycarpa extract.
Example 3 Reduced Expression of Pro-Inflammatory Cytokines
Problem:
The increased bacterial lode within acne lesions draws inflammatory cells into the area stimulated by the increased expression of pro-inflammatory cytokines. As acne lesions emerge, inflammation occurs as the skin attempts to heal itself Overall, redness of the skin surrounding the acne lesion is intensified by the release of pro-inflammatory cytokines.
Solution:
In vitro testing was used to examine the effect of plant extracts Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, and Cystoseira amentacea/Caespitosa Brachycarpa extract to reduce the expression of IL-8, IL-2, and TNF-α pro-inflammatory cytokines, which can contribute to a reduction in the intense erythema associated with acne lesions and acne prone skin.
Materials and Methods:
Human adult epidermal keratinocytes were cultured at 37° C. and 5.0% CO2 in standard growth medium. At 70-80% confluent, cells were treated with plant extracts for 5 h in the presence or absence of phorbol myristyl acetate. Following, all media was collected and assayed for inflammatory cytokine production analysis using the FaST Quant Kit—Following blocking, supernatant was added to each array. Each array contains triplicate spots for each cytokine. Arrays were incubated for 3 hours and treated with an antibody cocktail, containing one biotinylated antibody corresponding to each of the arrayed capture antibodies. Arrays were incubated for 1 h and incubated with a streptavidin-Cy5. Arrays were imaged on a Perkin-Elmer ScanArray 4000 confocal fluorescent imaging system. Array images were analyzed using Imaging Research ArrayVision software. Spot intensities were determined by subtracting background signal. Spot replicates were averaged and compared to the appropriate controls. Data was calculated as a percent change from appropriate controls.
Results:
A summary of the results is in FIG. 1. These data demonstrate that Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, and Cystoseira amentacea/Caespitosa Brachycarpa extract can act to reduce the expression of known inflammatory cytokines in human epidermal keratinocytes induced by chemical treatment. Together, these data support the ability of these botanical to reduce the potential for skin irritation associated with acne prone skin.
Example 4 Determining Efficacy of the Compositions of the Present Invention
The efficacy of compositions or active ingredients within a given composition of the present inventions can be determined by methods known to those of ordinary skill in the art. The following are non-limiting procedures that can be used in the context of the present invention. It should be recognized that other testing procedures can be used, including, for example, objective and subjective procedures. The active ingredients (e.g., Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, Pinus sylvestris bark extract, Ribes nigrum (Black Currant) leaf extract, Peumus boldus (Boldo) leaf extract, Spiraea ulmaria (Meadow Sweet) extract, Cystoseira amentacea/Caespitosa Brachycarpa extract, or an anti-acne ingredient (e.g., salicylic acid, benzylic acid, benzoyl peroxide, tretinoin, etc.) or any combination thereof, can be tested for their skin efficacy by using the composition vehicles identified in Tables 1 and 2. As noted in these Tables, the active ingredients and concentration ranges can vary.
Acne treatment can be visually monitored by applying a treatment composition to acne associated symptoms (e.g., open or closed comedones, papules (pimples), pustules, nodulocystic lesions, etc.) and inspecting the symptom over a period of time (e.g., 1, 2, 3, 4, 5, 6, days, 1, 2, 3, 4, weeks, 1, 2, 3, 4, months, etc.). Similarly, Acne prevention can be visually monitored by applying a prevention composition to skin susceptible of exhibiting an acne associated symptom (e.g., chin, cheek, eye, nose, forehead, etc., skin of a child, teenage, young adult, adult, or senior citizen) and inspecting the skin over a period of time. Further, the existence of symptoms associated with acne treatment (e.g., dry, flaky, or scaly skin or irritated skin) can be visually inspected.
Skin moisture/hydration can be measured by using impedance measurements with the Nova Dermal Phase Meter. The impedance meter measures changes in skin moisture content. The outer layer of the skin has distinct electrical properties. When skin is dry it conducts electricity very poorly. As it becomes more hydrated increasing conductivity results. Consequently, changes in skin impedance (related to conductivity) can be used to assess changes in skin hydration. The unit can be calibrated according to instrument instructions for each testing day. A notation of temperature and relative humidity can also be made. Subjects can be evaluated as follows: prior to measurement they can equilibrate in a room with defined humidity (e.g., 30-50%) and temperature (e.g., 68-72C). Three separate impedance readings can be taken on each side of the face, recorded, and averaged. The T5 setting can be used on the impedance meter which averages the impedance values of every five seconds application to the face. Changes can be reported with statistical variance and significance.
Skin clarity and the reduction in freckles and age spots can be evaluated using a Minolta Chromometer. Changes in skin color can be assessed to determine irritation potential due to product treatment using the a* values of the Minolta Chroma Meter. The a* value measures changes in skin color in the red region. This is used to determine whether a composition is inducing irritation. The measurements can be made on each side of the face and averaged, as left and right facial values. Skin clarity can also be measured using the Minolta Meter. The measurement is a combination of the a*, b, and L values of the Minolta Meter and is related to skin brightness, and correlates well with skin smoothness and hydration. Skin reading is taken as above. In one non-limiting aspect, skin clarity can be described as L/C where C is chroma and is defined as (a2+b2)1/2.
Skin dryness, surface fine lines, skin smoothness, and skin tone can be evaluated with clinical grading techniques. For example, clinical grading of skin dryness can be determined by a five point standard Kligman Scale: (0) skin is soft and moist; (1) skin appears normal with no visible dryness; (2) skin feels slightly dry to the touch with no visible flaking; (3) skin feels dry, tough, and has a whitish appearance with some scaling; and (4) skin feels very dry, rough, and has a whitish appearance with scaling. Evaluations can be made independently by two clinicians and averaged.
Clinical grading of skin tone can be performed via a ten point analog numerical scale: (10) even skin of uniform, pinkish brown color. No dark, erythremic, or scaly patches upon examination with a hand held magnifying lens. Microtexture of the skin very uniform upon touch; (7) even skin tone observed without magnification. No scaly areas, but slight discolorations either due to pigmentation or erythema. No discolorations more than 1 cm in diameter; (4) both skin discoloration and uneven texture easily noticeable. Slight scaliness. Skin rough to the touch in some areas; and (1) uneven skin coloration and texture. Numerous areas of scaliness and discoloration, either hypopigmented, erythremic or dark spots. Large areas of uneven color more than 1 cm in diameter. Evaluations were made independently by two clinicians and averaged.
Clinical grading of skin smoothness can be analyzed via a ten point analog numerical scale: (10) smooth, skin is moist and glistening, no resistance upon dragging finger across surface; (7) somewhat smooth, slight resistance; (4) rough, visibly altered, friction upon rubbing; and (1) rough, flaky, uneven surface. Evaluations were made independently by two clinicians and averaged.
Skin smoothness and wrinkle reduction can also be assessed visually by using the methods disclosed in Packman et al. (1978). For example, at each subject visit, the depth, shallowness and the total number of superficial facial lines (SFLs) of each subject can be carefully scored and recorded. A numerical score was obtained by multiplying a number factor times a depth/width/length factor. Scores are obtained for the eye area and mouth area (left and right sides) and added together as the total wrinkle score.
Skin firmness can be measured using a Hargens ballistometer, a device that evaluates the elasticity and firmness of the skin by dropping a small body onto the skin and recording its first two rebound peaks. The ballistometry is a small lightweight probe with a relatively blunt tip (4 square mm-contact area) was used. The probe penetrates slightly into the skin and results in measurements that are dependent upon the properties of the outer layers of the skin, including the stratum corneum and outer epidermis and some of the dermal layers.
Skin softness/suppleness can be evaluated using the Gas Bearing Electrodynamometer, an instrument that measures the stress/strain properties of the skin. The viscoelastic properties of skin correlate with skin moisturization. Measurements can be obtained on the predetermined site on the cheek area by attaching the probe to the skin surface with double-stick tape. A force of approximately 3.5 gm can be applied parallel to the skin surface and the skin displacement is accurately measured. Skin suppleness can then be calculated and is expressed as DSR (Dynamic Spring Rate in gm/mm).
The appearance of lines and wrinkles on the skin can be evaluated using replicas, which is the impression of the skin's surface. Silicone rubber like material can be used. The replica can be analyzed by image analysis. Changes in the visibility of lines and wrinkles can be objectively quantified via the taking of silicon replicas form the subjects' face and analyzing the replicas image using a computer image analysis system. Replicas can be taken from the eye area and the neck area, and photographed with a digital camera using a low angle incidence lighting. The digital images can be analyzed with an image processing program and the are of the replicas covered by wrinkles or fine lines was determined.
The surface contour of the skin can be measured by using the profilometer/Stylus method. This includes either shining a light or dragging a stylus across the replica surface. The vertical displacement of the stylus can be fed into a computer via a distance transducer, and after scanning a fixed length of replica a cross-sectional analysis of skin profile can be generated as a two-dimensional curve. This scan can be repeated any number of times along a fix axis to generate a simulated 3-D picture of the skin. Ten random sections of the replicas using the stylus technique can be obtained and combined to generate average values. The values of interest include Ra which is the arithmetic mean of all roughness (height) values computed by integrating the profile height relative to the mean profile height. Rt which is the maximum vertical distance between the highest peak and lowest trough, and Rz which is the mean peak amplitude minus the mean peak height. Values are given as a calibrated value in mm. Equipment should be standardized prior to each use by scanning metal standards of know values. Ra Value can be computed by the following equation: Ra=Standardize roughness; lm=the traverse (scan) length; and y=the absolute value of the location of the profile relative to the mean profile height (x-axis).
In other non-limiting aspects, the efficacy of the compositions of the present invention can be evaluated by using a skin analog, such as, for example, MELANODERM™. Melanocytes, one of the cells in the skin analog, stain positively when exposed to L-dihydroxyphenyl alanine (L-DOPA), a precursor of melanin. The skin analog, MELANODERM™, can be treated with a variety of bases containing the compositions and whitening agents of the present invention or with the base alone as a control. Alternatively, an untreated sample of the skin analog can be used as a control.
All of the compositions and/or methods disclosed and claimed in this specification can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of particular embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

Claims (12)

The invention claimed is:
1. A method of treating acne comprising topically applying to skin in need thereof a composition comprising:
(a) Arctium lappa root extract;
(b) Epilobium angustifolium extract; and
(c) Cystoseira amentacea/Caespitosa Brachycarpa extract,
wherein the composition further comprises salicylic acid, benzoyl peroxide, benzoic acid, or tretinoin.
2. The method of claim 1, wherein the composition is applied to a comedone, a papule, a pustule, or a nodulocystic lesion on the skin.
3. The method of claim 1, wherein the composition comprises:
(d) water;
(e) salicylic acid or benzoyl peroxide or a combination thereof;
(f) butylene glycol or propylene glycol or a combination thereof; and
(g) citric acid.
4. The method of claim 3, wherein the composition comprises:
(d) at least 50% by weight of water;
(e) 0.1 to 3% by weight of salicylic acid or benzoyl peroxide or a combination thereof;
(f) 0.005 to 10% by weight of butylene glycol or propylene glycol or a combination thereof; and
(g) 0.01 to 0.5% by weight of citric acid.
5. The method of claim 3, wherein the composition includes salicylic acid.
6. The method of claim 3, wherein the composition includes benzoyl peroxide.
7. The method of claim 3, wherein the composition further comprises:
(h) sodium C14-15 olefin sulfonate;
(i) cocamidopropyl betaine;
(j) sodium chloride;
(k) disodium EDTA; and
(l) phenoxyethanol.
8. The method of claim 7, wherein the composition comprises at least 65% by weight of water and:
(h) 15 to 20% by weight of sodium C14-15 olefin sulfonate;
(i) 4 to 8% by weight of cocamidopropyl betaine;
(j) 1 to 3% by weight of sodium chloride;
(k) 0.1 to 1% by weight of disodium EDTA; and
(l) 0.1 to 1% by weight of phenoxyethanol.
9. The composition of claim 1, wherein the composition comprises salicylic acid.
10. The composition of claim 1, wherein the composition comprises benzoyl peroxide.
11. The composition of claim 1, wherein the composition comprises benzoic acid.
12. The composition of claim 1, wherein the composition comprises tretinoin.
US12/768,450 2009-04-27 2010-04-27 Botanical anti-acne formulations Active 2031-06-25 US8440237B2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US12/768,450 US8440237B2 (en) 2009-04-27 2010-04-27 Botanical anti-acne formulations
US13/326,138 US8481090B2 (en) 2009-04-27 2011-12-14 Botanical formulations
US13/907,500 US8747926B2 (en) 2009-04-27 2013-05-31 Botanical formulations
US14/266,382 US9561198B2 (en) 2009-04-27 2014-04-30 Botanical formulations
US15/388,541 US10682381B2 (en) 2009-04-27 2016-12-22 Botanical formulations
US16/260,875 US10953058B2 (en) 2009-04-27 2019-01-29 Botanical formulations
US17/173,746 US11638735B2 (en) 2009-04-27 2021-02-11 Botanical formulations
US18/123,711 US20240050505A1 (en) 2009-04-27 2023-03-20 Botanical formulations
US18/538,812 US20240108673A1 (en) 2009-04-27 2023-12-13 Botanical formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17304209P 2009-04-27 2009-04-27
US12/768,450 US8440237B2 (en) 2009-04-27 2010-04-27 Botanical anti-acne formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/326,138 Continuation US8481090B2 (en) 2009-04-27 2011-12-14 Botanical formulations

Publications (2)

Publication Number Publication Date
US20100303854A1 US20100303854A1 (en) 2010-12-02
US8440237B2 true US8440237B2 (en) 2013-05-14

Family

ID=43017568

Family Applications (9)

Application Number Title Priority Date Filing Date
US12/768,450 Active 2031-06-25 US8440237B2 (en) 2009-04-27 2010-04-27 Botanical anti-acne formulations
US13/326,138 Active 2030-05-11 US8481090B2 (en) 2009-04-27 2011-12-14 Botanical formulations
US13/907,500 Active US8747926B2 (en) 2009-04-27 2013-05-31 Botanical formulations
US14/266,382 Active 2031-01-21 US9561198B2 (en) 2009-04-27 2014-04-30 Botanical formulations
US15/388,541 Active 2030-06-10 US10682381B2 (en) 2009-04-27 2016-12-22 Botanical formulations
US16/260,875 Active 2030-10-06 US10953058B2 (en) 2009-04-27 2019-01-29 Botanical formulations
US17/173,746 Active 2030-07-08 US11638735B2 (en) 2009-04-27 2021-02-11 Botanical formulations
US18/123,711 Abandoned US20240050505A1 (en) 2009-04-27 2023-03-20 Botanical formulations
US18/538,812 Pending US20240108673A1 (en) 2009-04-27 2023-12-13 Botanical formulations

Family Applications After (8)

Application Number Title Priority Date Filing Date
US13/326,138 Active 2030-05-11 US8481090B2 (en) 2009-04-27 2011-12-14 Botanical formulations
US13/907,500 Active US8747926B2 (en) 2009-04-27 2013-05-31 Botanical formulations
US14/266,382 Active 2031-01-21 US9561198B2 (en) 2009-04-27 2014-04-30 Botanical formulations
US15/388,541 Active 2030-06-10 US10682381B2 (en) 2009-04-27 2016-12-22 Botanical formulations
US16/260,875 Active 2030-10-06 US10953058B2 (en) 2009-04-27 2019-01-29 Botanical formulations
US17/173,746 Active 2030-07-08 US11638735B2 (en) 2009-04-27 2021-02-11 Botanical formulations
US18/123,711 Abandoned US20240050505A1 (en) 2009-04-27 2023-03-20 Botanical formulations
US18/538,812 Pending US20240108673A1 (en) 2009-04-27 2023-12-13 Botanical formulations

Country Status (2)

Country Link
US (9) US8440237B2 (en)
CN (2) CN105816498A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10500152B2 (en) 2014-03-10 2019-12-10 Mary Kay Inc. Skin lightening compositions
US10780041B2 (en) 2011-12-19 2020-09-22 Mary Kay Inc. Combination of plant extracts to improve skin tone

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440237B2 (en) 2009-04-27 2013-05-14 Mary Kay Inc. Botanical anti-acne formulations
CN102085169B (en) * 2011-01-30 2012-08-29 广州中涵生物科技有限公司 Preparation for dissolving blackheads and synchronously refining pores
US20120225107A1 (en) * 2011-03-04 2012-09-06 Caridad Hechavarria Stable skin and scar treatment composition
US8932656B1 (en) 2011-09-20 2015-01-13 Aja Henderson Oil blend for skin treatment
US9446089B1 (en) 2011-09-20 2016-09-20 Aja Henderson Oil blend for skin treatment
US20130323228A1 (en) * 2012-05-31 2013-12-05 Mary Kay Inc. Cleansing and anti-acne composition
US9861670B2 (en) 2013-03-13 2018-01-09 Santalis Healthcare Corporation Stabilized cream formulations comprising sandalwood oil
GB2512343A (en) * 2013-03-27 2014-10-01 Reckitt Benckiser Brands Ltd Skincare compositions
CN103535385B (en) * 2013-10-25 2015-07-15 北京桑普生物化学技术有限公司 Plant extract and synergist contained antimicrobial composition
DE202014010979U1 (en) 2013-12-17 2017-02-23 Mary Kay Inc . Applicator devices for skincare products
FR3015898B1 (en) * 2013-12-31 2016-02-05 Virbac Sa TOPICAL COMPOSITION COMPRISING BOLDO AND QUEEN EXTRACTS FOR ANIMALS, AND USES THEREOF
CA3000854A1 (en) 2015-10-07 2017-04-13 Santalis Pharmaceuticals, Inc. Sandalwood oil and its uses related to oral mucositis
MX2018009197A (en) 2016-02-03 2018-11-09 Sony Corp Terminal device, base station device, and communications method.
KR101818211B1 (en) 2016-04-05 2018-01-12 주식회사 엘지생활건강 Composition for prevention or treatment of oral disease comprising Arctill fructus Extract
CN106606453A (en) * 2017-01-11 2017-05-03 杭州菲丝凯化妆品有限公司 Moisture-retaining anti-acne cream and preparation method thereof
CN107007792A (en) * 2017-04-27 2017-08-04 福建省康馨生物科技有限公司 A kind of pharmaceutical composition of nti-freckle and preparation method thereof, preparation and application
CN107308027A (en) * 2017-07-11 2017-11-03 广州市巧美化妆品有限公司 A kind of succinct production technology of sapphire whitening
CN108210975B (en) * 2018-02-06 2020-12-22 青岛海洋生物医药研究院 Collagen dressing for treating acne
WO2019160398A1 (en) * 2018-02-14 2019-08-22 Tiran Saucedo Jose Method and pharmaceutical composition for the treatment of vaginal and skin infections
FR3080032B1 (en) 2018-04-13 2020-04-17 Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic USE OF A NEW COMPOSITION TO PREVENT OR SLOW DOWN THE APPEARANCE OF SIGNS OF INFLAMMATION
FR3080030B1 (en) * 2018-04-13 2020-04-24 Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic USE OF A NEW COMPOSITION TO PREVENT OR SLOW DOWN THE APPEARANCE OF THE AESTHETIC SIGNS RELATED TO THE PRESENCE OF EXCESS SEBUM
IL259395B (en) * 2018-05-16 2021-03-25 Gigi Cosmetic Laboratories Ltd Cosmetic composition for use in the treatment and prevention of acne-prone skin
US11464728B1 (en) 2018-11-30 2022-10-11 Jeffrey Alan Deane Lip care composition
CN113395957A (en) * 2018-12-25 2021-09-14 莱雅公司 Composition for cleaning keratin materials
CN110711147B (en) * 2019-11-03 2022-09-20 广州悦荟化妆品有限公司 Facial mask with acne removing and acne mark repairing functions
IT202000013393A1 (en) * 2020-06-05 2021-12-05 Francesco Sestito PHYTOTHERAPY COMPOSITIONS FOR TOPICAL USE
CN114209618A (en) * 2021-11-23 2022-03-22 湖北省麦诗特生物科技有限公司 A facial cream composition for promoting skin barrier health, and its preparation method
FR3137284A1 (en) * 2022-06-29 2024-01-05 Laboratoires Nigy COMPOSITION FOR THE PREVENTION AND TREATMENT OF SKIN HYPERPIGMENTATION BASED ON NIACINAMIDE OR ONE OF ITS DERIVATIVES AND A CYSTOSEIRA ALGAE EXTRACT

Citations (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0641557A1 (en) 1993-09-07 1995-03-08 L'oreal Dermatologic or cosmetic composition made up by an oil in water emulsion based on oily globules coated with a lamellar liquid crystall coating
EP0692257A1 (en) 1994-07-14 1996-01-17 Emil Flachsmann AG Process of preparation of poor pesticide active principles concentrates from plants
US5639460A (en) 1995-06-07 1997-06-17 Raymond; Hal C. Aqueous plant extract having antiviral activity
KR970067591A (en) 1996-03-04 1997-10-13 오노 시게오 Projection exposure equipment
EP0826372A2 (en) 1996-09-03 1998-03-04 Emil Flachsmann AG Process of preparation of a stable, homogeneous, free or quite free of impurities extract
CN1190232A (en) 1996-10-08 1998-08-12 株式会社日立制作所 Plasma display, driving apparatus of plasma display panel and driving system thereof
EP0915693A1 (en) 1996-08-02 1999-05-19 Plum Kemi Produktion A/S An oil-in-water emulsion for use on human skin for cleansing, preserving or improving the condition of the skin
DE19849107A1 (en) 1998-09-17 2000-03-30 Tittel Ohg Dr Process for removing unwanted, toxic alkaloids from plants or from plant preparations
EP1029531A2 (en) 1999-02-17 2000-08-23 Bristol-Myers Squibb Company Vegetal extract as cosmetic agent for skin
WO2001068576A1 (en) 2000-03-10 2001-09-20 Applied Genetics Incorporated Dermatics Dermatological compounds
EP1194111A2 (en) 1999-07-13 2002-04-10 Pharmasol GmbH Uv radiation reflecting or absorbing agents, protecting against harmful uv radiation and reinforcing the natural skin barrier
EP1200317A1 (en) 1999-08-03 2002-05-02 Giorgio Panin A device for spray dispensing a composition for topical application comprising vitamin e and essential fatty acids
WO2002085965A1 (en) 2001-03-09 2002-10-31 Henkel Kommanditgesellschaft Auf Aktien Cosmetic sponges
WO2002089758A1 (en) 2001-05-10 2002-11-14 Cognis France S.A. Use of oligomeric proanthrocyanidins
KR100357824B1 (en) 1998-04-04 2003-01-24 주식회사 태평양 Cosmetic compounds containing natural products for treating and preventing acne
EP1283713A2 (en) 2000-05-12 2003-02-19 Bengt Krister Olson Combined cartilage and plant extract compositions
US6528490B2 (en) 1999-09-10 2003-03-04 Fytoken Products, Inc. Oenothein medicaments
KR20030044506A (en) 2001-11-30 2003-06-09 한국전자통신연구원 LPM-based CAM look-up-table managing method, the apparatus thereof and the recording medium thereof
WO2003070152A2 (en) 2002-02-23 2003-08-28 Cognis Deutschland Gmbh & Co. Kg Anti-aging agents containing plant extracts from the genus arctium
US20030170319A1 (en) * 2002-01-11 2003-09-11 Shrirang Netke Nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
WO2003075862A2 (en) 2002-03-08 2003-09-18 Accantia Holdings Limited Formulation
CA2386648A1 (en) * 2002-05-16 2003-11-16 Fytokem Products Inc. Compositions and methods for managing bacterial skin conditions
WO2003099244A1 (en) 2002-05-27 2003-12-04 Beiersdorf Ag Cosmetic and/or dermatological preparation comprising 2,3-dibenzylbutyrolactones
US20030224064A1 (en) * 2002-04-25 2003-12-04 Kling William O. Anti-acne compositions and methods of use
DE10251709A1 (en) 2002-08-02 2004-02-12 Ysl Beaute Active substances for stimulating the human beta-defensins of type 2 and / or type 3 and cosmetic or pharmaceutical compositions which contain such active substances
EP1407879A1 (en) 2001-05-24 2004-04-14 Toray Industries, Inc. Heat-resistant resin film with metal layer and wiring board and method for manufacturing them
WO2004045575A1 (en) 2002-11-19 2004-06-03 Kimberly-Clark Worldwide, Inc. Antioxidant-containing wipes and absorbent products
DE10320603A1 (en) 2002-11-19 2004-06-09 Coletica Method for testing the activity of a possible active substance which can inhibit the enzymatic activity of phospholipase A2
WO2004050108A1 (en) 2002-11-25 2004-06-17 Societe Celatour Oil compositions obtained from non-heated plant parts, introduced ground and non-heated in the press, extracted by cold pressing
WO2004066912A2 (en) 2003-01-31 2004-08-12 Technion Research & Development Foundation Ltd. Anti-inflammatory compositions and uses thereof
US20040161524A1 (en) 2001-06-21 2004-08-19 Yasushi Sakai Process for producing a plant extract containing plant powder
EP1455722A1 (en) 2001-12-22 2004-09-15 Kimberly-Clark Worldwide, Inc. System for skin health of absorbent article wearers
WO2004078189A1 (en) 2003-03-03 2004-09-16 Bioplanta Arzneimittel Gmbh Use of rutin and isoharmnetin for treating depressive states and depression and other emotion disorders
EP1466589A1 (en) 2003-04-09 2004-10-13 L'oreal Stable cosmetic composition comprising a fatty acid glyceride, an alcohol and a silicone emulsifier
WO2004105737A2 (en) 2003-05-30 2004-12-09 Arc Pharmaceuticals, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
EP1493421A1 (en) 2003-07-02 2005-01-05 L'oreal Topical composition containing an organopolysiloxane elastomer, and an aqueous dispersion of silicon bloc copolymer
WO2005011716A1 (en) 2003-07-21 2005-02-10 Henkel Kommanditgesellschaft Auf Aktien Prebiotically active plant extracts
US20050080160A1 (en) 2003-08-14 2005-04-14 Seabrook Samuel G. Paints, coatings and polymers containing phytochemical agents and methods for making and using same
CN1627956A (en) 2002-02-08 2005-06-15 庄臣及庄臣有限公司 Compositions containing oat straw and willowherb extract
DE10333245A1 (en) 2003-07-21 2005-07-28 Henkel Kgaa Cosmetic or pharmaceutical composition e.g. useful for promoting the growth of desirable skin microorganisms comprises a plant extract with prebiotic activity on the skin
WO2005075623A1 (en) 2004-01-20 2005-08-18 Huntsman Petrochemical Corporation Novel acylalkylisethionate esters and applications in consumer products
DE102004011968A1 (en) 2004-03-10 2005-09-29 Henkel Kgaa Cosmetic or pharmaceutical composition e.g. useful for promoting the growth of desirable skin microorganisms comprises a plant extract with prebiotic activity on the skin
WO2005095959A2 (en) 2004-03-29 2005-10-13 Howard Murad Methods for treating dermatological conditions in a patient
EP1602354A1 (en) 2003-03-10 2005-12-07 Meiji Seika Kaisha, Ltd. Hair treatment composition and hair cosmetic for damaged hair
CN1713889A (en) 2002-11-07 2005-12-28 株式会社高丝 Composition for preparation for external use on skin and method of using the same
US20060018867A1 (en) 2004-05-12 2006-01-26 Ichimaru Pharcos Co., Ltd Cosmetic composition and production thereof
WO2006032143A1 (en) 2004-09-23 2006-03-30 Arc Pharmaceuticals, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
WO2006051246A1 (en) 2004-11-11 2006-05-18 The Boots Company Plc Topical compositions comprising myrica gale oil
WO2006053415A1 (en) 2004-11-18 2006-05-26 Biopharmacopae Design International Inc. Plant extract having matrix metalloprotease inhibiting activity and dermatological uses thereof
WO2006067945A1 (en) 2004-12-22 2006-06-29 Pola Chemical Industries Inc. External skin agent comprising modified clay for preventing inflammation
WO2006068759A2 (en) 2004-11-22 2006-06-29 Magellan Companies, Inc. Liposomes containing phytochemical agents and methods for making and using same
US20060165644A1 (en) 2002-08-14 2006-07-27 Fancl Corporation Cosmetics
DE102005063063A1 (en) 2005-12-29 2006-10-05 Henkel Kgaa Topical cosmetic or dermatological composition, useful to treat e.g. skin aging; and to improve the optical image of the skin, comprises a carrier, particle forming, sorbing sebum active agent and a regular sebum active substance
EP1708677A2 (en) 2004-01-07 2006-10-11 E-L Management Corp. Cosmetic composition containing a protein and an enzyme inhibitor
US20060233845A1 (en) 2002-02-28 2006-10-19 Gerold Lukowski Micro/nanoparticle obtained from lipid-containing marine organisms for use in pharmaceutics and cosmetics
WO2006128032A2 (en) 2005-05-24 2006-11-30 Wellgen, Inc. Compositions and methods for the prevention and treatment of conditions associated with inflammation
EP1728519A2 (en) 2005-06-01 2006-12-06 Siegfried Natterer Polar supporting and broad-band resonant preparation
CN1883449A (en) 2006-06-12 2006-12-27 乔爱娴 A cosmetic composition and preparation method thereof
DE102005028386A1 (en) 2005-06-20 2007-01-04 Wella Aktiengesellschaft Product delivery system for spraying hair and skin cosmetic cleansing compositions
WO2007007293A2 (en) 2005-07-13 2007-01-18 L'oreal Cosmetic composition of stick type
WO2007007296A1 (en) 2005-07-13 2007-01-18 L'oreal Cosmetic makeup and/or care process
WO2007007290A1 (en) 2005-07-13 2007-01-18 L'oreal Cosmetic makeup and/or care process
WO2007007288A2 (en) 2005-07-13 2007-01-18 L'oreal Cosmetic makeup and/or care assembly
WO2007007292A2 (en) 2005-07-13 2007-01-18 L'oreal Cosmetic makeup and/or care product
WO2007007291A2 (en) 2005-07-13 2007-01-18 L'oreal Cosmetic makeup and/or care process
WO2007007287A2 (en) 2005-07-13 2007-01-18 L'oreal Cosmetic makeup and/or care process
WO2007016223A2 (en) 2005-07-28 2007-02-08 Magellan Companies, Inc. Filter materials with biocidal phytochemical agents
EP1759688A1 (en) 2005-09-05 2007-03-07 L'Oréal Cosmetic method for the care of greasy skin and kit therefor
WO2007044945A2 (en) 2005-10-13 2007-04-19 Gu, Jennifer, L. Mineral collagen chelates and methods of making and using same
DE202007002978U1 (en) 2007-02-27 2007-05-16 Certmedica International Gmbh Aqueous disinfecting gel preparation, useful as skin disinfectant or hand disinfectant, comprises alcoholic active agents, thickening agents, active components such as sedatives, healing promoters and/or inflammation inhibitors, and water
DE102006054621A1 (en) 2005-11-17 2007-05-31 Engelhard Lyon Herbal extracts for HAS stimulation, in particular for HAS2 stimulation
WO2007077292A1 (en) 2006-01-05 2007-07-12 Artto Aurola Visible light detecting semiconductor radiation detector
EP1813252A1 (en) 2006-01-30 2007-08-01 Henkel Kommanditgesellschaft auf Aktien Cosmetic composition for matting the scalp
WO2007085902A2 (en) 2005-07-19 2007-08-02 Foamix Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
DE202007008601U1 (en) 2007-06-20 2007-09-13 Ginkgo Gmbh Means for the treatment of hair and use of the agent
WO2007113830A2 (en) 2006-04-04 2007-10-11 Avner Shemer Kit for treating skin infection
WO2007116147A1 (en) 2006-04-10 2007-10-18 Laboratoire Aguettant Healing composition
US20070248633A1 (en) 2006-04-21 2007-10-25 L'oreal Compositions containing a hydroxylated diphenylmethane compound, methods of use
WO2007122422A2 (en) 2006-04-13 2007-11-01 The Boots Company Plc Composition and uses thereof
WO2007146816A2 (en) 2006-06-09 2007-12-21 T.F.H. Publications, Inc. Tamanu oil products
US20070297999A1 (en) 2006-06-21 2007-12-27 L'oreal Kit containing an acidic composition and a composition based on a hydroxyalkyl urea
US20080008673A1 (en) 2006-07-03 2008-01-10 Claudie Willemin Compositions comprising at least one C-glycoside derivative
WO2008032212A2 (en) 2006-09-08 2008-03-20 Foamix Ltd. Colored or colorable foamable composition and foam
WO2008034703A1 (en) 2006-09-20 2008-03-27 L'oreal Obtaining a controlled coloured effect from a vegetable extract
WO2008034702A1 (en) 2006-09-20 2008-03-27 L'oreal Process for the preparation of a cosmetic composition comprising plant extracts and hydrolysable compounds
WO2008042331A2 (en) 2006-09-29 2008-04-10 Monosol Rx Llc Film embedded packaging and method of making same

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798053A (en) 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US3755560A (en) 1971-06-30 1973-08-28 Dow Chemical Co Nongreasy cosmetic lotions
US4421769A (en) 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
US4509949A (en) 1983-06-13 1985-04-09 The B. F. Goodrich Company Water thickening agents consisting of copolymers of crosslinked acrylic acids and esters
GB8401206D0 (en) 1984-01-17 1984-02-22 Allied Colloids Ltd Polymers and aqueous solutions
GB8414950D0 (en) 1984-06-12 1984-07-18 Allied Colloids Ltd Cationic polyelectrolytes
GB8622797D0 (en) 1986-09-22 1986-10-29 Allied Colloids Ltd Polymeric particles
EP0262945B1 (en) 1986-10-01 1994-01-05 Ciba Specialty Chemicals Water Treatments Limited Water soluble polymeric compositions
GB8909095D0 (en) 1989-04-21 1989-06-07 Allied Colloids Ltd Thickened aqueous compositions
US5087445A (en) 1989-09-08 1992-02-11 Richardson-Vicks, Inc. Photoprotection compositions having reduced dermal irritation
US5011681A (en) 1989-10-11 1991-04-30 Richardson-Vicks, Inc. Facial cleansing compositions
JPH05286843A (en) * 1992-04-08 1993-11-02 Max Fuakutaa Kk Skin cosmetic containing culture mixture of suehirotake @(3754/24)schizophyllum commue)
US5411741A (en) 1993-07-29 1995-05-02 Zaias; Nardo Method and composition for skin depigmentation
US5939082A (en) 1995-11-06 1999-08-17 The Procter & Gamble Company Methods of regulating skin appearance with vitamin B3 compound
JPH09268118A (en) 1996-04-01 1997-10-14 Kao Corp Skin color-improving beautifier
CN1165012A (en) * 1997-01-21 1997-11-19 石小雷 Instant stop itching spray agent for mosquito and insect bite and its preparation method
US5997890A (en) 1997-05-23 1999-12-07 The Procter & Gamble Company Skin care compositions and method of improving skin appearance
KR100525842B1 (en) 1997-11-19 2006-01-12 주식회사 엘지생활건강 Nicotinamide-containing ceramide liquid crystal and cosmetic composition comprising the same
FR2779058B1 (en) 1998-05-29 2003-02-21 Dior Christian Parfums USE OF AT LEAST ONE COSMETICALLY ACCEPTABLE SAPONIN OR SAPOGENOL AS A COSMETIC AGENT FOR INCREASING THE QUANTITY OF COLLAGEN IV IN THE DERMO-EPIDERMAL JUNCTION
US6224888B1 (en) 1999-02-12 2001-05-01 The Procter & Gamble Company Cosmetic compositions
KR20010110001A (en) 2000-06-05 2001-12-12 최희진 Cosmetics composition containing Psoralea corylifolia L. extracts
US20020022040A1 (en) 2000-07-10 2002-02-21 The Proctor & Gamble Company Methods of enhancing delivery of oil-soluble skin care actives
KR20010000479A (en) 2000-10-02 2001-01-05 이정심 Eating natural Skin massage & Method of basic make-up
JP2002265343A (en) 2001-03-07 2002-09-18 Ichimaru Pharcos Co Ltd Cosmetic composition
KR20030089710A (en) 2001-04-06 2003-11-22 가부시키가이샤 도요학코 Cosmetic materials and process for producing the same
KR20020080657A (en) 2001-04-17 2002-10-26 주식회사 참 존 Cosmetics comprising Albizzia bark extracts for antioxidation
KR100443588B1 (en) 2002-01-25 2004-08-09 나드리화장품주식회사 Cosmetic composition containing paeonia suffruticosa andrews extract and albizzia julibrissin dura extract having anti-ageing effect
US6863897B2 (en) 2002-03-22 2005-03-08 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Stabilization of resorcinol derivatives in cosmetic compositions
FR2838341B1 (en) 2002-04-10 2007-07-27 Gelyma MARINE ALGAE EXTRACT OF THE GENUS CYSTOSEIRA AND USE IN CARE PRODUCTS
WO2003101389A2 (en) * 2002-05-29 2003-12-11 Bio-Defense Nutritionals Relief of aids symptoms
EP1539204A1 (en) * 2002-08-30 2005-06-15 Biopharmacopae Design International Inc. Plant extracts for treatment of angiogenesis and metastasis
KR100512690B1 (en) 2002-11-29 2005-09-07 나드리화장품주식회사 Cosmetic composition containing bletilla striata and leontopodium alpinum extract
US20040166069A1 (en) 2003-02-21 2004-08-26 Gupta Shyam K. Boosting Tyrosinase Inhibiting Activity of Skin Whitening and Sunscreen Compositions
MXPA06011905A (en) * 2003-04-16 2007-04-16 Lavender Hill Projects Pty Ltd Herbal composition.
US7195781B2 (en) * 2003-04-21 2007-03-27 Bronhilda Miketin Method for treatment of skin disorders
ATE381313T1 (en) 2003-06-13 2008-01-15 Procter & Gamble SKIN CARE DEVICE WITH SKIN BLEACHING PRODUCT
ES2335484T3 (en) 2003-07-03 2010-03-29 THE PROCTER & GAMBLE COMPANY SELF-GRADING COMPOSITIONS THAT INCLUDE A COMPOSITE OF VITAMIN B3 WATER SOLUBLE AND AN ALFA-HYDROXICARBONILIC SELF-GRADING AGENT.
JP4090402B2 (en) * 2003-07-30 2008-05-28 日本オプネクスト株式会社 Semiconductor optical amplifier and optical module using the same
WO2005044214A1 (en) 2003-11-06 2005-05-19 Unilever Plc Improved cosmetic composition comprising vitamin b3, vitamin b6 and an organic acid
US7416869B2 (en) * 2004-08-19 2008-08-26 Lonza Ltd. Enzyme delivery systems, application in water based products
KR101072133B1 (en) 2004-01-15 2011-10-10 (주)아모레퍼시픽 Skin whitening composition having synergic whitening effect
JP2007530607A (en) 2004-03-30 2007-11-01 ユニリーバー・ナームローゼ・ベンノートシヤープ Skin lightening composition comprising vitamins and flavonoids
BRPI0418729B1 (en) 2004-04-08 2019-01-29 Vdf Futureceuticals Inc method for producing a cosmetic composition of cherry coffee
US20060008538A1 (en) 2004-07-07 2006-01-12 Wu Jeffrey M Methods of treating the skin
KR20060106310A (en) * 2005-04-07 2006-10-12 안인경 Soap for whitening using oriental herb
CN101170990B (en) 2005-05-03 2012-11-07 荷兰联合利华有限公司 Skin lightening composition comprising a conjugated linoleic acid and niacinamide
US7615546B2 (en) 2005-08-19 2009-11-10 Bioderm Research Topical delivery system for phytosterols
CN1840117A (en) * 2006-01-26 2006-10-04 葛强 Dermatosis-treating medicine
JP2007210915A (en) 2006-02-08 2007-08-23 Kose Corp Skin preparation for external use
US20080031833A1 (en) 2006-03-13 2008-02-07 Oblong John E Combined energy and topical composition application for regulating the condition of mammalian skin
US8912172B2 (en) 2006-06-19 2014-12-16 Kuraray Co., Ltd. Skin external preparation containing triterpenic acid
KR100841072B1 (en) 2007-01-15 2008-06-24 유지은 Natural cereal whitening composition
KR101277530B1 (en) 2007-01-26 2013-06-21 주식회사 엘지생활건강 Composition for scalp-care before haircoloring
DE602007001128D1 (en) 2007-03-07 2009-06-25 Indena Spa Formulations with extracts of Cynara scolymus and Phaseolus vulgaris for the treatment of obesity
US20080305059A1 (en) 2007-06-06 2008-12-11 Chaudhuri Ratan K Skin lightening compositions and methods
US20090016935A1 (en) * 2007-07-09 2009-01-15 Andrianov Alexander K Coating formulations including polyphosphazene polyelectrolytes and biologically active agents and asperities coated with such formulations
US8063005B2 (en) 2007-12-10 2011-11-22 Sanyasi Raju Kalidindi Personal care formulations with simultaneous exfoliant, cleansing and moisturizing properties
EP2234594A4 (en) 2007-12-19 2013-01-16 Elc Man Llc Compositions and methods for treating skin with extract from trametes
US20110086060A1 (en) 2008-04-11 2011-04-14 Florence Bidamant Novel compositions and their use
US8119698B2 (en) 2008-06-30 2012-02-21 Conopco, Inc. Sunscreen formula vanishing cream
US20090324661A1 (en) 2008-06-30 2009-12-31 Conopco, Inc., D/B/A Unilever Niacinamide containing cosmetic compositions with improved skinfeel properties
AU2009268225A1 (en) 2008-07-10 2010-01-14 Unilever Plc A method of lightening skin
US20110117227A1 (en) 2008-07-31 2011-05-19 Coreana Cosmetics, Co., Ltd. Cosmetic composition for anti-aging of the skin comprising phaseolus radiatus seed extracts by fermentation and enzyme treatment
US20100040701A1 (en) * 2008-08-12 2010-02-18 Neal Schwartz Compound for exfoliating skin
KR101052189B1 (en) 2008-08-14 2011-08-01 영농조합법인대나무바이오 Skin Whitening Composition
KR101172114B1 (en) 2008-11-17 2012-08-10 (주)아모레퍼시픽 Skin whitening cosmetic composition containing natural crop powders as exfoliation surface skin cells
FR2939316B1 (en) 2008-12-05 2012-08-10 Limousine D Applic Biolog Ditesilab Soc Ind COSMETIC USE OF ACTIVATORS OF AUTOPHAGIA OF SKIN CELLS.
KR20100064451A (en) 2008-12-05 2010-06-15 (주)아모레퍼시픽 Composition for external skin application for improvement in wrinkle containing leontopodic acid
US8247405B2 (en) 2008-12-10 2012-08-21 Conopco, Inc. Skin lightening compositions with acetylcholinesterase inhibitors
US9676696B2 (en) 2009-01-29 2017-06-13 The Procter & Gamble Company Regulation of mammalian keratinous tissue using skin and/or hair care actives
KR20100090530A (en) 2009-02-06 2010-08-16 애경산업(주) Extracts of albizzia julibrissin and oral composition for preventing and improving periodontal disease and cosmetic composition for preventing and improving skin aging
FR2942136B1 (en) 2009-02-13 2013-01-18 Gelyma USE OF EXTRACT FROM BROWN ALGAE OF THE GENUS HALIDRYS IN COSMETIC AND / OR DERMATOLOGICAL FIELDS
DE102009001821A1 (en) 2009-03-24 2010-10-07 Ihp Gmbh - Innovations For High Performance Microelectronics / Leibniz-Institut Für Innovative Mikroelektronik Packet-forwarding protocol acceleration module and method for a transceiver for fast forwarding of data packets
US8440237B2 (en) * 2009-04-27 2013-05-14 Mary Kay Inc. Botanical anti-acne formulations
GB0912481D0 (en) 2009-07-17 2009-08-26 Reckitt Benckiser Healthcare I Skincare compositions
FR2949684B1 (en) 2009-09-04 2011-12-16 Silab Sa ACTIVE PRINCIPLE FROM CANDIDA SAITOANA AND COSMETIC USE FOR DETOXIFICATION OF SKIN CELLS
GB0915964D0 (en) 2009-09-11 2009-10-28 Reckitt Benckiser Healthcare I Cosmetic composition
US8084504B2 (en) 2009-10-02 2011-12-27 Johnson & Johnson Consumer Companies, Inc. High-clarity aqueous concentrates of 4-hexylresorcinol
US20110081305A1 (en) 2009-10-02 2011-04-07 Steven Cochran Compositions comprising a skin-lightening resorcinol and a skin darkening agent
CN102188331B (en) 2010-03-03 2016-08-31 株式会社太平洋 Hair or head skin cosmetics composite
KR101776071B1 (en) 2010-04-21 2017-09-07 (주)아모레퍼시픽 Composition containing red sword bean extract for anti-aging and whitening
BR112012029995A2 (en) 2010-05-27 2016-08-02 Leti Sl Lab topical pharmaceutical or cosmetic composition useful for the treatment of diseases or conditions that pass through a cornified envelope maturation deficit
CN101904804A (en) 2010-06-09 2010-12-08 珀莱雅(湖州)化妆品有限公司 Skin whitening complex prepared from algae serving as main raw materials
KR101275351B1 (en) 2010-06-29 2013-06-17 (주)아모레퍼시픽 Cosmetic Composition for Preventing Skin Aging
CN103002869B (en) 2010-07-22 2015-08-05 宝洁公司 For suppressing compositions and the method for PAR2 keratinocytes
US8435541B2 (en) 2010-09-02 2013-05-07 Bath & Body Works Brand Management, Inc. Topical compositions for inhibiting matrix metalloproteases and providing antioxidative activities
KR101773523B1 (en) 2010-11-30 2017-09-04 (주)아모레퍼시픽 Cosmetic composition containing hydrophilic crystalline materials
KR20120068224A (en) 2010-12-17 2012-06-27 웅진코웨이주식회사 Preparation method gold coated granule and cosmetic composition comprising thereof
SG10201602752XA (en) 2011-01-07 2016-05-30 Allergan Inc Melanin modification compositions and methods of use
KR101269993B1 (en) 2011-02-09 2013-05-31 주식회사 후너스바이오 Cosmetic Composition
KR101790738B1 (en) 2011-02-11 2017-10-27 주식회사 케미메디 Composition for Treatment of Brain Cancers and Beauty Expenses Composition Comprising Extract of Albizziae Cortex
EP2522330A1 (en) 2011-05-09 2012-11-14 DSM IP Assets B.V. Use of resveratrol and an edelweiss extract
MX356540B (en) 2011-05-10 2018-06-01 Mary Kay Inc Cosmetic compositions.
EP2736484B1 (en) * 2011-07-25 2020-12-16 PCR Technology Holdings, LC Botanical antioxidant compositions
FR2980362B1 (en) 2011-09-27 2013-10-04 Sederma Sa NOVEL COSMETIC USE OF ALBIZIA JULIBRISSIN EXTRACT AND CORRESPONDING TOPICAL COMPOSITION
US20130195925A1 (en) 2011-11-03 2013-08-01 Vaskin, Llc Anti aging application and method for treating aging
KR20210046089A (en) 2011-12-19 2021-04-27 마리 케이 인코포레이티드 Combination of plant extrats to improve skin tone
KR101502687B1 (en) 2013-07-11 2015-03-16 주식회사 바이오에프디엔씨 Anti-aging and Anti-inflammatory and Anti-oxidant Cosmetic Composition including Beans Placenta Cell Cultures Extracts
KR102323049B1 (en) 2014-03-10 2021-11-05 마리 케이 인코포레이티드 Skin lightening compositions
KR101638551B1 (en) 2014-07-10 2016-07-12 (주)제니트리 Improving composition for skin-antiwinkle and skin-whitening, Preparing method thereof, and Skin-externals containing the same
KR101918266B1 (en) 2016-12-02 2018-11-30 주식회사 아이피어리스 The Extracting Method of Active Protein
KR20200041130A (en) 2018-10-11 2020-04-21 임성은 Multi-body moisturizer using grape leaf extract and red bean extrat

Patent Citations (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0641557A1 (en) 1993-09-07 1995-03-08 L'oreal Dermatologic or cosmetic composition made up by an oil in water emulsion based on oily globules coated with a lamellar liquid crystall coating
EP0692257A1 (en) 1994-07-14 1996-01-17 Emil Flachsmann AG Process of preparation of poor pesticide active principles concentrates from plants
US5639460A (en) 1995-06-07 1997-06-17 Raymond; Hal C. Aqueous plant extract having antiviral activity
KR970067591A (en) 1996-03-04 1997-10-13 오노 시게오 Projection exposure equipment
EP0915693A1 (en) 1996-08-02 1999-05-19 Plum Kemi Produktion A/S An oil-in-water emulsion for use on human skin for cleansing, preserving or improving the condition of the skin
EP0826372A2 (en) 1996-09-03 1998-03-04 Emil Flachsmann AG Process of preparation of a stable, homogeneous, free or quite free of impurities extract
CN1190232A (en) 1996-10-08 1998-08-12 株式会社日立制作所 Plasma display, driving apparatus of plasma display panel and driving system thereof
KR100357824B1 (en) 1998-04-04 2003-01-24 주식회사 태평양 Cosmetic compounds containing natural products for treating and preventing acne
EP1027064A1 (en) 1998-09-17 2000-08-16 Emil Flachsmann AG Method for removing undesirable toxic alkaloids from plants or vegetable preparations
DE19849107A1 (en) 1998-09-17 2000-03-30 Tittel Ohg Dr Process for removing unwanted, toxic alkaloids from plants or from plant preparations
EP1029531A2 (en) 1999-02-17 2000-08-23 Bristol-Myers Squibb Company Vegetal extract as cosmetic agent for skin
EP1194111A2 (en) 1999-07-13 2002-04-10 Pharmasol GmbH Uv radiation reflecting or absorbing agents, protecting against harmful uv radiation and reinforcing the natural skin barrier
EP1200317A1 (en) 1999-08-03 2002-05-02 Giorgio Panin A device for spray dispensing a composition for topical application comprising vitamin e and essential fatty acids
US6528490B2 (en) 1999-09-10 2003-03-04 Fytoken Products, Inc. Oenothein medicaments
WO2001068576A1 (en) 2000-03-10 2001-09-20 Applied Genetics Incorporated Dermatics Dermatological compounds
EP1283713A2 (en) 2000-05-12 2003-02-19 Bengt Krister Olson Combined cartilage and plant extract compositions
WO2002085965A1 (en) 2001-03-09 2002-10-31 Henkel Kommanditgesellschaft Auf Aktien Cosmetic sponges
WO2002089758A1 (en) 2001-05-10 2002-11-14 Cognis France S.A. Use of oligomeric proanthrocyanidins
EP1407879A1 (en) 2001-05-24 2004-04-14 Toray Industries, Inc. Heat-resistant resin film with metal layer and wiring board and method for manufacturing them
US20040161524A1 (en) 2001-06-21 2004-08-19 Yasushi Sakai Process for producing a plant extract containing plant powder
KR20030044506A (en) 2001-11-30 2003-06-09 한국전자통신연구원 LPM-based CAM look-up-table managing method, the apparatus thereof and the recording medium thereof
EP1455722A1 (en) 2001-12-22 2004-09-15 Kimberly-Clark Worldwide, Inc. System for skin health of absorbent article wearers
US20030170319A1 (en) * 2002-01-11 2003-09-11 Shrirang Netke Nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
CN1627956A (en) 2002-02-08 2005-06-15 庄臣及庄臣有限公司 Compositions containing oat straw and willowherb extract
WO2003070152A2 (en) 2002-02-23 2003-08-28 Cognis Deutschland Gmbh & Co. Kg Anti-aging agents containing plant extracts from the genus arctium
US20060233845A1 (en) 2002-02-28 2006-10-19 Gerold Lukowski Micro/nanoparticle obtained from lipid-containing marine organisms for use in pharmaceutics and cosmetics
WO2003075862A2 (en) 2002-03-08 2003-09-18 Accantia Holdings Limited Formulation
US20030224064A1 (en) * 2002-04-25 2003-12-04 Kling William O. Anti-acne compositions and methods of use
CA2386648A1 (en) * 2002-05-16 2003-11-16 Fytokem Products Inc. Compositions and methods for managing bacterial skin conditions
WO2003099244A1 (en) 2002-05-27 2003-12-04 Beiersdorf Ag Cosmetic and/or dermatological preparation comprising 2,3-dibenzylbutyrolactones
DE10251709A1 (en) 2002-08-02 2004-02-12 Ysl Beaute Active substances for stimulating the human beta-defensins of type 2 and / or type 3 and cosmetic or pharmaceutical compositions which contain such active substances
US20060165644A1 (en) 2002-08-14 2006-07-27 Fancl Corporation Cosmetics
CN1713889A (en) 2002-11-07 2005-12-28 株式会社高丝 Composition for preparation for external use on skin and method of using the same
WO2004045575A1 (en) 2002-11-19 2004-06-03 Kimberly-Clark Worldwide, Inc. Antioxidant-containing wipes and absorbent products
DE10320603A1 (en) 2002-11-19 2004-06-09 Coletica Method for testing the activity of a possible active substance which can inhibit the enzymatic activity of phospholipase A2
WO2004050108A1 (en) 2002-11-25 2004-06-17 Societe Celatour Oil compositions obtained from non-heated plant parts, introduced ground and non-heated in the press, extracted by cold pressing
WO2004066912A2 (en) 2003-01-31 2004-08-12 Technion Research & Development Foundation Ltd. Anti-inflammatory compositions and uses thereof
WO2004078189A1 (en) 2003-03-03 2004-09-16 Bioplanta Arzneimittel Gmbh Use of rutin and isoharmnetin for treating depressive states and depression and other emotion disorders
EP1602354A1 (en) 2003-03-10 2005-12-07 Meiji Seika Kaisha, Ltd. Hair treatment composition and hair cosmetic for damaged hair
US20060165636A1 (en) 2003-03-10 2006-07-27 Kouhei Hasebe Hair treatment composition and hair cosmetic for damaged hair
WO2004093840A2 (en) 2003-04-09 2004-11-04 L'oreal Method for demonstrating the draining activity of a cosmetic treatment, and composition having a draining activity
EP1466589A1 (en) 2003-04-09 2004-10-13 L'oreal Stable cosmetic composition comprising a fatty acid glyceride, an alcohol and a silicone emulsifier
WO2004105737A2 (en) 2003-05-30 2004-12-09 Arc Pharmaceuticals, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
EP1493421A1 (en) 2003-07-02 2005-01-05 L'oreal Topical composition containing an organopolysiloxane elastomer, and an aqueous dispersion of silicon bloc copolymer
WO2005011716A1 (en) 2003-07-21 2005-02-10 Henkel Kommanditgesellschaft Auf Aktien Prebiotically active plant extracts
DE10333245A1 (en) 2003-07-21 2005-07-28 Henkel Kgaa Cosmetic or pharmaceutical composition e.g. useful for promoting the growth of desirable skin microorganisms comprises a plant extract with prebiotic activity on the skin
US20060182708A1 (en) 2003-07-21 2006-08-17 Dirk Bockmuhl Prebiotically active plant extracts
US20050080160A1 (en) 2003-08-14 2005-04-14 Seabrook Samuel G. Paints, coatings and polymers containing phytochemical agents and methods for making and using same
EP1708677A2 (en) 2004-01-07 2006-10-11 E-L Management Corp. Cosmetic composition containing a protein and an enzyme inhibitor
WO2005075623A1 (en) 2004-01-20 2005-08-18 Huntsman Petrochemical Corporation Novel acylalkylisethionate esters and applications in consumer products
DE102004011968A1 (en) 2004-03-10 2005-09-29 Henkel Kgaa Cosmetic or pharmaceutical composition e.g. useful for promoting the growth of desirable skin microorganisms comprises a plant extract with prebiotic activity on the skin
WO2005095959A2 (en) 2004-03-29 2005-10-13 Howard Murad Methods for treating dermatological conditions in a patient
US20060018867A1 (en) 2004-05-12 2006-01-26 Ichimaru Pharcos Co., Ltd Cosmetic composition and production thereof
WO2006032143A1 (en) 2004-09-23 2006-03-30 Arc Pharmaceuticals, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
WO2006051246A1 (en) 2004-11-11 2006-05-18 The Boots Company Plc Topical compositions comprising myrica gale oil
WO2006053415A1 (en) 2004-11-18 2006-05-26 Biopharmacopae Design International Inc. Plant extract having matrix metalloprotease inhibiting activity and dermatological uses thereof
WO2006068759A2 (en) 2004-11-22 2006-06-29 Magellan Companies, Inc. Liposomes containing phytochemical agents and methods for making and using same
WO2006067945A1 (en) 2004-12-22 2006-06-29 Pola Chemical Industries Inc. External skin agent comprising modified clay for preventing inflammation
WO2006128032A2 (en) 2005-05-24 2006-11-30 Wellgen, Inc. Compositions and methods for the prevention and treatment of conditions associated with inflammation
EP1728519A2 (en) 2005-06-01 2006-12-06 Siegfried Natterer Polar supporting and broad-band resonant preparation
DE102005025156A1 (en) 2005-06-01 2006-12-07 Siegfried Natterer Polar support and broadband resonator preparation
DE102005028386A1 (en) 2005-06-20 2007-01-04 Wella Aktiengesellschaft Product delivery system for spraying hair and skin cosmetic cleansing compositions
WO2007007287A2 (en) 2005-07-13 2007-01-18 L'oreal Cosmetic makeup and/or care process
WO2007007293A2 (en) 2005-07-13 2007-01-18 L'oreal Cosmetic composition of stick type
WO2007007296A1 (en) 2005-07-13 2007-01-18 L'oreal Cosmetic makeup and/or care process
WO2007007290A1 (en) 2005-07-13 2007-01-18 L'oreal Cosmetic makeup and/or care process
WO2007007288A2 (en) 2005-07-13 2007-01-18 L'oreal Cosmetic makeup and/or care assembly
WO2007007292A2 (en) 2005-07-13 2007-01-18 L'oreal Cosmetic makeup and/or care product
WO2007007291A2 (en) 2005-07-13 2007-01-18 L'oreal Cosmetic makeup and/or care process
WO2007085902A2 (en) 2005-07-19 2007-08-02 Foamix Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
WO2007016223A2 (en) 2005-07-28 2007-02-08 Magellan Companies, Inc. Filter materials with biocidal phytochemical agents
EP1759688A1 (en) 2005-09-05 2007-03-07 L'Oréal Cosmetic method for the care of greasy skin and kit therefor
WO2007044945A2 (en) 2005-10-13 2007-04-19 Gu, Jennifer, L. Mineral collagen chelates and methods of making and using same
DE102006054621A1 (en) 2005-11-17 2007-05-31 Engelhard Lyon Herbal extracts for HAS stimulation, in particular for HAS2 stimulation
DE102005063063A1 (en) 2005-12-29 2006-10-05 Henkel Kgaa Topical cosmetic or dermatological composition, useful to treat e.g. skin aging; and to improve the optical image of the skin, comprises a carrier, particle forming, sorbing sebum active agent and a regular sebum active substance
WO2007077292A1 (en) 2006-01-05 2007-07-12 Artto Aurola Visible light detecting semiconductor radiation detector
EP1813252A1 (en) 2006-01-30 2007-08-01 Henkel Kommanditgesellschaft auf Aktien Cosmetic composition for matting the scalp
WO2007113830A2 (en) 2006-04-04 2007-10-11 Avner Shemer Kit for treating skin infection
WO2007116147A1 (en) 2006-04-10 2007-10-18 Laboratoire Aguettant Healing composition
WO2007122422A2 (en) 2006-04-13 2007-11-01 The Boots Company Plc Composition and uses thereof
US20070248633A1 (en) 2006-04-21 2007-10-25 L'oreal Compositions containing a hydroxylated diphenylmethane compound, methods of use
WO2007146816A2 (en) 2006-06-09 2007-12-21 T.F.H. Publications, Inc. Tamanu oil products
CN1883449A (en) 2006-06-12 2006-12-27 乔爱娴 A cosmetic composition and preparation method thereof
US20070297999A1 (en) 2006-06-21 2007-12-27 L'oreal Kit containing an acidic composition and a composition based on a hydroxyalkyl urea
US20080008673A1 (en) 2006-07-03 2008-01-10 Claudie Willemin Compositions comprising at least one C-glycoside derivative
WO2008032212A2 (en) 2006-09-08 2008-03-20 Foamix Ltd. Colored or colorable foamable composition and foam
WO2008034703A1 (en) 2006-09-20 2008-03-27 L'oreal Obtaining a controlled coloured effect from a vegetable extract
WO2008034702A1 (en) 2006-09-20 2008-03-27 L'oreal Process for the preparation of a cosmetic composition comprising plant extracts and hydrolysable compounds
WO2008042331A2 (en) 2006-09-29 2008-04-10 Monosol Rx Llc Film embedded packaging and method of making same
DE202007002978U1 (en) 2007-02-27 2007-05-16 Certmedica International Gmbh Aqueous disinfecting gel preparation, useful as skin disinfectant or hand disinfectant, comprises alcoholic active agents, thickening agents, active components such as sedatives, healing promoters and/or inflammation inhibitors, and water
DE202007008601U1 (en) 2007-06-20 2007-09-13 Ginkgo Gmbh Means for the treatment of hair and use of the agent

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"Abundance of Nature in Town's Reach," The Journal, May 1, 1999, Executive Motoring, p. 47.
"Garden Showcases Unique Plant Collection," Calgary Herold, Jun. 23, 1999, Gardens, VS16.
"Module One: Nature's Pain Relieving Substances," Aspirin Alternatives: The Top Natural Pain-Relieving Analgesics, Jun. 1, 1999, p. 52.
"The Skin Care Market," Household and Personal Products Industry, May 1, 2001, No. 5, vol. 38, p. 112.
In the yard, The Desert Sun; Aug. 5, 2006, p. 3F.
Kocmethka Veocity Mary Kay; Online, URL 6 pages accessed Dec. 17, 2012. *
Kocmethka Veocity Mary Kay; Online, URL<http://www.ugrei.net/forum/Kosmetika-Velocity-Mary-t12660.html&st=40> 6 pages accessed Dec. 17, 2012. *
Phillipson, J. New Drugs From Nature-It Could Be Yew; Phytotherapy Research 13 (1999) pp. 2-8. *
Phillipson, J. New Drugs From Nature—It Could Be Yew; Phytotherapy Research 13 (1999) pp. 2-8. *
Revilla et al. Comparison of Several Procedures Used for the Extraction of Anthocynains From Red Grapes; J. Agric. Food Chem. 1998, 46, pp. 4592-4597. *
Smet, P. Herbal Remedies; The New England Journal of Medicine 347. 25 (Dec. 2002), pp. 2046-2056. *
Winsome flowering veins; New Straits Times, Feb. 23, 2002, p. 8.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10780041B2 (en) 2011-12-19 2020-09-22 Mary Kay Inc. Combination of plant extracts to improve skin tone
US11865202B2 (en) 2011-12-19 2024-01-09 Mary Kay Inc. Combination of plant extracts to improve skin tone
US10500152B2 (en) 2014-03-10 2019-12-10 Mary Kay Inc. Skin lightening compositions

Also Published As

Publication number Publication date
CN101874822A (en) 2010-11-03
US20140017181A1 (en) 2014-01-16
US9561198B2 (en) 2017-02-07
US20240050505A1 (en) 2024-02-15
US10682381B2 (en) 2020-06-16
US11638735B2 (en) 2023-05-02
US8481090B2 (en) 2013-07-09
CN105816498A (en) 2016-08-03
US20210290716A1 (en) 2021-09-23
US20190151387A1 (en) 2019-05-23
US20120087878A1 (en) 2012-04-12
US10953058B2 (en) 2021-03-23
US20170136077A1 (en) 2017-05-18
US20140234367A1 (en) 2014-08-21
US20100303854A1 (en) 2010-12-02
US20240108673A1 (en) 2024-04-04
US8747926B2 (en) 2014-06-10

Similar Documents

Publication Publication Date Title
US11638735B2 (en) Botanical formulations
US11596813B2 (en) Skin care formulations
US8993006B2 (en) Topical skin care formulations
US11865202B2 (en) Combination of plant extracts to improve skin tone
US10639344B2 (en) Skin care formulation
US20100260695A1 (en) Combination of plant extracts to improve skin tone
US20130149361A1 (en) Encapsulated pink tourmaline for skin

Legal Events

Date Code Title Description
AS Assignment

Owner name: MARY KAY INC., TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HINES, MICHELLE;FLORENCE, TIFFANY;SIGNING DATES FROM 20100618 TO 20100803;REEL/FRAME:024813/0857

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8